Cross	O
talk	O
between	O
cell	O
death	O
and	O
cell	O
cycle	O
progression	O
:	O
BCL-2	B-protein
regulates	O
NFAT	B-protein
-mediated	O
activation	O
.	O

BCL-2-deficient	B-cell_line
T	I-cell_line
cells	I-cell_line
demonstrate	O
accelerated	O
cell	O
cycle	O
progression	O
and	O
increased	O
apoptosis	O
following	O
activation	O
.	O

Increasing	O
the	O
levels	O
of	O
BCL-2	B-protein
retarded	O
the	O
G0	O
--	O
>	O
S	O
transition	O
,	O
sustained	O
the	O
levels	O
of	O
cyclin-dependent	B-protein
kinase	I-protein
inhibitor	O
p27Kip1	O
,	O
and	O
repressed	O
postactivation	O
death	O
.	O

Proximal	O
signal	O
transduction	O
events	O
and	O
immediate	B-DNA
early	I-DNA
gene	I-DNA
transcription	O
were	O
unaffected	O
.	O

However	O
,	O
the	O
transcription	O
and	O
synthesis	O
of	O
interleukin	B-protein
2	I-protein
and	O
other	O
delayed	O
early	O
cytokines	B-protein
were	O
markedly	O
attenuated	O
by	O
BCL-2	B-protein
.	O

In	O
contrast	O
,	O
a	O
cysteine	O
protease	O
inhibitor	O
that	O
also	O
blocks	O
apoptosis	O
had	O
no	O
substantial	O
affect	O
upon	O
cytokine	B-protein
production	O
.	O

InterleUkin	B-protein
2	I-protein
expression	O
requires	O
several	O
transcription	B-protein
factors	I-protein
of	O
which	O
nuclear	O
translocation	O
of	O
NFAT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	O
and	O
NFAT	B-protein
-mediated	O
transactivation	O
were	O
impaired	O
by	O
BCL-2	B-protein
.	O

Thus	O
,	O
select	O
genetic	O
aberrations	O
in	O
the	O
apoptotic	O
pathway	O
reveal	O
a	O
cell	O
autonomous	O
coregulation	O
of	O
activation	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

93	NULL
,	NULL
pp	NULL
.	NULL

9545-9552	NULL
,	NULL
September	NULL
1996	NULL
Cell	NULL
Biology	NULL
This	NULL
contribution	NULL
is	NULL
part	NULL
of	NULL
the	NULL
special	NULL
series	NULL
of	NULL
Inaugural	NULL
Articles	NULL
by	NULL
members	NULL
of	NULL
the	NULL
National	NULL
Academy	NULL
of	NULL
Sciences	NULL
elected	NULL
on	NULL
April	NULL
25	NULL
,	NULL
1995	NULL
.	NULL

Cross	NULL
talk	NULL
between	NULL
cell	NULL
death	NULL
and	NULL
cell	NULL
cycle	NULL
progression	NULL
:	NULL
BCL-2	NULL
regulates	NULL
NFAT-mediated	NULL
activation	NULL
GERALD	NULL
P.	NULL
LInNETTE*	NULL
,	NULL
YinG	NULL
L*	NULL
,	NULL
KEvIN	NULL
ROTH	NULL
,	NULL
AND	NULL
STANLEY	NULL
J.	NULL
KorsmEyERT	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
and	NULL
Division	NULL
of	NULL
Molecular	NULL
Oncology	NULL
,	NULL
Departments	NULL
of	NULL
Medicine	NULL
and	NULL
Pathology	NULL
,	NULL
Washington	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
63110	NULL
Contributed	NULL
by	NULL
Stanley	NULL
J.	NULL
Korsmeyer	NULL
,	NULL
July	NULL
17	NULL
,	NULL
1996	NULL
ABSTRACT	NULL
BCL-2-deficient	NULL
T	NULL
cells	NULL
demonstrate	NULL
accelerated	NULL
cell	NULL
cycle	NULL
progression	NULL
and	NULL
increased	NULL
apoptosis	NULL
following	NULL
activation	NULL
.	NULL

Increasing	NULL
the	NULL
levels	NULL
of	NULL
BCL-2	NULL
retarded	NULL
the	NULL
G	NULL
,	NULL
-	NULL
>	NULL
S	NULL
transition	NULL
,	NULL
sustained	NULL
the	NULL
levels	NULL
of	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitor	NULL
p27*	NULL
``	NULL
``	NULL
``	NULL
,	NULL
and	NULL
repressed	NULL
postactivation	NULL
death	NULL
.	NULL

Proximal	NULL
signal	NULL
transduction	NULL
events	NULL
and	NULL
immediate	NULL
early	NULL
gene	NULL
transcription	NULL
were	NULL
unaffected	NULL
.	NULL

However	NULL
,	NULL
the	NULL
transcription	NULL
and	NULL
synthesis	NULL
of	NULL
interleukin	NULL
2	NULL
and	NULL
other	NULL
delayed	NULL
early	NULL
cytokines	NULL
were	NULL
markedly	NULL
attenuated	NULL
by	NULL
BCL-2	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
a	NULL
cysteine	NULL
protease	NULL
inhibitor	NULL
that	NULL
also	NULL
blocks	NULL
apoptosis	NULL
had	NULL
no	NULL
substantial	NULL
affect	NULL
upon	NULL
cytokine	NULL
production	NULL
.	NULL

Interleukin	NULL
2	NULL
expression	NULL
requires	NULL
several	NULL
transcription	NULL
factors	NULL
of	NULL
which	NULL
nuclear	NULL
translocation	NULL
of	NULL
NFAT	NULL
(	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
)	NULL
and	NULL
NFAT-mediated	NULL
transactivation	NULL
were	NULL
impaired	NULL
by	NULL
BCL-2	NULL
.	NULL

Thus	NULL
,	NULL
select	NULL
genetic	NULL
aberrations	NULL
in	NULL
the	NULL
apoptotic	NULL
pathway	NULL
reveal	NULL
a	NULL
cell	NULL
autonomous	NULL
coregulation	NULL
of	NULL
activation	NULL
.	NULL

Homeostasis	NULL
of	NULL
cell	NULL
numbers	NULL
requires	NULL
a	NULL
carefully	NULL
orchestrated	NULL
balance	NULL
between	NULL
input	NULL
(	NULL
proliferation	NULL
)	NULL
and	NULL
output	NULL
(	NULL
cell	NULL
death	NULL
)	NULL
processes	NULL
.	NULL

Important	NULL
questions	NULL
remain	NULL
as	NULL
to	NULL
how	NULL
these	NULL
two	NULL
reactions	NULL
are	NULL
coordinated	NULL
to	NULL
achieve	NULL
a	NULL
remarkably	NULL
invariant	NULL
number	NULL
of	NULL
cells	NULL
within	NULL
each	NULL
lineage	NULL
.	NULL

One	NULL
thesis	NULL
would	NULL
hold	NULL
that	NULL
two	NULL
independent	NULL
genetic	NULL
pathways	NULL
exist	NULL
that	NULL
control	NULL
cellular	NULL
proliferation	NULL
or	NULL
cell	NULL
death	NULL
.	NULL

In	NULL
this	NULL
scenario	NULL
,	NULL
balance	NULL
would	NULL
be	NULL
attained	NULL
by	NULL
communication	NULL
with	NULL
extracellular	NULL
cues	NULL
.	NULL

This	NULL
includes	NULL
the	NULL
well-documented	NULL
competition	NULL
between	NULL
cells	NULL
for	NULL
limited	NULL
survival	NULL
factors	NULL
in	NULL
their	NULL
surrounding	NULL
microenvironment	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Incontrovertible	NULL
evidence	NULL
now	NULL
exists	NULL
for	NULL
a	NULL
distinct	NULL
genetic	NULL
pathway	NULL
controlling	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

The	NULL
Be/-2	NULL
protooncogene	NULL
isolated	NULL
from	NULL
the	NULL
chromosomal	NULL
breakpoint	NULL
of	NULL
t	NULL
(	NULL
14	NULL
;	NULL
18	NULL
)	NULL
bearing	NULL
B	NULL
cell	NULL
lymphoma	NULL
(	NULL
2-4	NULL
)	NULL
serves	NULL
as	NULL
a	NULL
repressor	NULL
of	NULL
apoptosis	NULL
in	NULL
mammalian	NULL
cells	NULL
(	NULL
5-7	NULL
)	NULL
.	NULL

Gain	NULL
of	NULL
function	NULL
studies	NULL
that	NULL
overexpressed	NULL
wild-type	NULL
Bc/-2	NULL
extended	NULL
survival	NULL
rather	NULL
than	NULL
promoting	NULL
proliferation	NULL
and	NULL
lead	NULL
to	NULL
an	NULL
excess	NULL
of	NULL
lymphocytes	NULL
that	NULL
eventually	NULL
progressed	NULL
to	NULL
B	NULL
and	NULL
T	NULL
cell	NULL
malignancy	NULL
(	NULL
8-10	NULL
)	NULL
.	NULL

Loss	NULL
of	NULL
function	NULL
analysis	NULL
that	NULL
knocked	NULL
out	NULL
the	NULL
Bel-2	NULL
or	NULL
Bcl-x	NULL
,	NULL
death	NULL
repressor	NULL
resulted	NULL
in	NULL
the	NULL
loss	NULL
of	NULL
cells	NULL
from	NULL
selected	NULL
lineages	NULL
(	NULL
11-13	NULL
)	NULL
.	NULL

While	NULL
hematopoietic	NULL
lineages	NULL
appear	NULL
to	NULL
develop	NULL
normally	NULL
in	NULL
the	NULL
Bc/-2-deficient	NULL
mice	NULL
,	NULL
they	NULL
display	NULL
a	NULL
striking	NULL
inability	NULL
to	NULL
maintain	NULL
homeostasis	NULL
of	NULL
lymphocytes	NULL
with	NULL
apoptotic	NULL
loss	NULL
of	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
.	NULL

While	NULL
established	NULL
gene	NULL
products	NULL
clearly	NULL
regulate	NULL
apoptosis	NULL
,	NULL
it	NULL
is	NULL
unclear	NULL
whether	NULL
they	NULL
have	NULL
roles	NULL
that	NULL
affect	NULL
other	NULL
pathways	NULL
.	NULL

A	NULL
second	NULL
thesis	NULL
would	NULL
argue	NULL
that	NULL
a	NULL
balanced	NULL
population	NULL
of	NULL
cells	NULL
would	NULL
be	NULL
difficult	NULL
to	NULL
maintain	NULL
unless	NULL
a	NULL
cell	NULL
autonomous	NULL
coordination	NULL
existed	NULL
between	NULL
decisions	NULL
to	NULL
divide	NULL
and	NULL
decisions	NULL
to	NULL
die	NULL
.	NULL

A	NULL
number	NULL
of	NULL
experimental	NULL
models	NULL
argue	NULL
that	NULL
improper	NULL
activation	NULL
and	NULL
aberrant	NULL
cell	NULL
cycle	NULL
progression	NULL
can	NULL
prompt	NULL
individual	NULL
cells	NULL
to	NULL
initiate	NULL
suicide	NULL
.	NULL

For	NULL
example	NULL
,	NULL
overexpression	NULL
of	NULL
Myc	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
serum	NULL
results	NULL
in	NULL
apoptosis	NULL
(	NULL
14	NULL
)	NULL
.	NULL

This	NULL
has	NULL
been	NULL
envisioned	NULL
as	NULL
signaling	NULL
a	NULL
conflict	NULL
or	NULL
perhaps	NULL
the	NULL
dual	NULL
capacity	NULL
of	NULL
Myc	NULL
as	NULL
a	NULL
transcription	NULL
factor	NULL
to	NULL
initiate	NULL
a	NULL
death	NULL
as	NULL
9545	NULL
well	NULL
as	NULL
a	NULL
proliferation	NULL
program	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Mice	NULL
deficient	NULL
in	NULL
a	NULL
cell	NULL
cycle	NULL
regulator	NULL
,	NULL
the	NULL
retinoblastoma	NULL
gene	NULL
product	NULL
(	NULL
Rb	NULL
)	NULL
,	NULL
demonstrate	NULL
abnormal	NULL
mitotic	NULL
figures	NULL
as	NULL
well	NULL
as	NULL
death	NULL
of	NULL
embryonic	NULL
neurons	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
the	NULL
overexpression	NULL
of	NULL
E2F	NULL
,	NULL
which	NULL
mimics	NULL
Rb	NULL
deficiency	NULL
,	NULL
can	NULL
also	NULL
result	NULL
in	NULL
apoptosis	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

From	NULL
this	NULL
perspective	NULL
,	NULL
there	NULL
would	NULL
appear	NULL
to	NULL
be	NULL
a	NULL
capacity	NULL
to	NULL
identify	NULL
aberrations	NULL
in	NULL
proliferation	NULL
that	NULL
would	NULL
trigger	NULL
the	NULL
apoptotic	NULL
elimination	NULL
of	NULL
dangerous	NULL
cells	NULL
.	NULL

We	NULL
chose	NULL
to	NULL
approach	NULL
this	NULL
complex	NULL
issue	NULL
from	NULL
the	NULL
opposite	NULL
perspective	NULL
,	NULL
asking	NULL
whether	NULL
regulators	NULL
of	NULL
cell	NULL
death	NULL
impact	NULL
the	NULL
cellular	NULL
proliferation	NULL
pathway	NULL
.	NULL

To	NULL
pursue	NULL
this	NULL
,	NULL
we	NULL
elected	NULL
to	NULL
contrast	NULL
genetic	NULL
models	NULL
of	NULL
Be/-2	NULL
loss-of-function	NULL
(	NULL
If	NULL
)	NULL
and	NULL
Bcl-2	NULL
transgenic	NULL
gain-of-function	NULL
(	NULL
gf	NULL
)	NULL
using	NULL
cells	NULL
from	NULL
these	NULL
mice	NULL
that	NULL
were	NULL
otherwise	NULL
normal	NULL
.	NULL

Be/-2	NULL
homozygous	NULL
knockout	NULL
(	NULL
-/-	NULL
)	NULL
,	NULL
heterozygous	NULL
(	NULL
+/-	NULL
)	NULL
,	NULL
wild-type	NULL
(	NULL
+/+	NULL
)	NULL
,	NULL
and	NULL
IckP	NULL
``	NULL
-Bel-2	NULL
transgen-ics	NULL
(	NULL
which	NULL
overexpress	NULL
wild-type	NULL
protein	NULL
,	NULL
also	NULL
referred	NULL
to	NULL
as	NULL
Bcl-2	NULL
gf	NULL
)	NULL
provide	NULL
a	NULL
gradient	NULL
of	NULL
BCL-2	NULL
levels	NULL
within	NULL
T	NULL
cells	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
any	NULL
effects	NULL
upon	NULL
activation	NULL
and	NULL
proliferation	NULL
noted	NULL
in	NULL
Bel-2	NULL
gf	NULL
cells	NULL
would	NULL
be	NULL
considerably	NULL
strengthened	NULL
by	NULL
an	NULL
opposite	NULL
effect	NULL
in	NULL
Bel-2	NULL
If	NULL
cells	NULL
.	NULL

We	NULL
selected	NULL
T	NULL
cells	NULL
as	NULL
a	NULL
representative	NULL
model	NULL
of	NULL
resting	NULL
,	NULL
Go	NULL
,	NULL
mature	NULL
cells	NULL
with	NULL
distinct	NULL
stages	NULL
of	NULL
transition	NULL
between	NULL
Go	NULL
-	NULL
>	NULL
S	NULL
phase	NULL
.	NULL

T	NULL
cells	NULL
require	NULL
BCL-2	NULL
to	NULL
maintain	NULL
homeostasis	NULL
,	NULL
and	NULL
a	NULL
well-defined	NULL
signal	NULL
transduction	NULL
pathway	NULL
interconnects	NULL
the	NULL
T	NULL
cell	NULL
surface	NULL
antigen	NULL
receptor	NULL
to	NULL
cell	NULL
cycle	NULL
regulators	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Steps	NULL
can	NULL
be	NULL
separated	NULL
into	NULL
mitogenesis	NULL
in	NULL
which	NULL
proximal	NULL
signal	NULL
transduction	NULL
events	NULL
lead	NULL
to	NULL
immediate	NULL
early	NULL
gene	NULL
expression	NULL
during	NULL
the	NULL
transition	NULL
from	NULL
Go	NULL
-	NULL
>	NULL
G1	NULL
and	NULL
into	NULL
a	NULL
later	NULL
critical	NULL
event	NULL
in	NULL
mid	NULL
G	NULL
;	NULL
phase	NULL
in	NULL
which	NULL
the	NULL
expression	NULL
and	NULL
signaling	NULL
by	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
a	NULL
physiologic	NULL
growth	NULL
factor	NULL
,	NULL
are	NULL
required	NULL
for	NULL
progression	NULL
into	NULL
S	NULL
phase	NULL
(	NULL
21	NULL
)	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
Preparations	NULL
and	NULL
Culture	NULL
.	NULL

Single	NULL
cell	NULL
suspensions	NULL
were	NULL
prepared	NULL
from	NULL
spleen	NULL
or	NULL
thymus	NULL
and	NULL
erythrocytes	NULL
were	NULL
lysed	NULL
in	NULL
0.17	NULL
M	NULL
NHC	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Splenic	NULL
T	NULL
cells	NULL
were	NULL
purified	NULL
by	NULL
negative	NULL
selection	NULL
with	NULL
immunomagnetic	NULL
beads	NULL
as	NULL
described	NULL
except	NULL
that	NULL
incubation	NULL
of	NULL
cells	NULL
with	NULL
magnetic	NULL
beads	NULL
was	NULL
performed	NULL
for	NULL
1	NULL
hr	NULL
at	NULL
4°C	NULL
(	NULL
22	NULL
)	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
always	NULL
90-95	NULL
%	NULL
pure	NULL
as	NULL
judged	NULL
by	NULL
CD3	NULL
staining	NULL
and	NULL
were	NULL
>	NULL
95	NULL
%	NULL
viable	NULL
.	NULL

Freshly	NULL
isolated	NULL
splenic	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
24-well	NULL
plates	NULL
(	NULL
Costar	NULL
)	NULL
in	NULL
1	NULL
ml	NULL
complete	NULL
media	NULL
(	NULL
Iscove	NULL
's	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
heat-inactivated	NULL
FCS	NULL
,	NULL
100	NULL
units/ml	NULL
penicillin	NULL
,	NULL
50	NULL
units/ml	NULL
streptomycin	NULL
,	NULL
1	NULL
mM	NULL
Hepes	NULL
,	NULL
and	NULL
5	NULL
x	NULL
10~°	NULL
M	NULL
2-mercaptoetha-nol	NULL
)	NULL
at	NULL
37°C	NULL
,	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
/95	NULL
%	NULL
oxygen	NULL
.	NULL

Splenic	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
in	NULL
24-well	NULL
plates	NULL
coated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
.	NULL

Abbreviations	NULL
:	NULL
If	NULL
,	NULL
loss-of-function	NULL
;	NULL
gf	NULL
,	NULL
gain-of-function	NULL
;	NULL
IL	NULL
,	NULL
interleu-	NULL
kin	NULL
;	NULL
RT-PCR	NULL
,	NULL
reverse	NULL
transcription-PCR	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
;	NULL
cdk	NULL
,	NULL
cyclin-dependent	NULL
kinase	NULL
.	NULL

*G.P.L	NULL
.	NULL

and	NULL
Y.L	NULL
.	NULL

are	NULL
co-first	NULL
authors	NULL
as	NULL
they	NULL
contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
.	NULL

*To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

9546	NULL
Cell	NULL
Biology	NULL
:	NULL
Linette	NULL
et	NULL
al	NULL
.	NULL

Briefly	NULL
,	NULL
protein-A	NULL
purified	NULL
anti-mouse	NULL
CD3	NULL
mAb	NULL
(	NULL
145-2C11	NULL
,	NULL
PharMingen	NULL
)	NULL
was	NULL
diluted	NULL
in	NULL
0.05	NULL
M	NULL
Tris	NULL
(	NULL
pH	NULL
9.3	NULL
)	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
250	NULL
pl	NULL
and	NULL
allowed	NULL
to	NULL
absorb	NULL
overnight	NULL
at	NULL
4°C	NULL
.	NULL

Afterwards	NULL
,	NULL
wells	NULL
were	NULL
washed	NULL
twice	NULL
and	NULL
3-5	NULL
x	NULL
10°	NULL
T	NULL
cells	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
1	NULL
mil	NULL
complete	NULL
medium	NULL
were	NULL
added	NULL
to	NULL
individual	NULL
wells	NULL
.	NULL

When	NULL
indicated	NULL
,	NULL
anti-murine	NULL
CD28	NULL
mAb	NULL
(	NULL
23	NULL
)	NULL
(	NULL
PV-1	NULL
,	NULL
a	NULL
gift	NULL
from	NULL
C.	NULL
June	NULL
,	NULL
Naval	NULL
Medical	NULL
Research	NULL
Institute	NULL
)	NULL
(	NULL
24	NULL
)	NULL
was	NULL
added	NULL
in	NULL
fluid	NULL
phase	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
5	NULL
ug/ml	NULL
.	NULL

Jurkat	NULL
T	NULL
cell	NULL
line	NULL
(	NULL
25	NULL
)	NULL
(	NULL
E6-1	NULL
clone	NULL
,	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
)	NULL
was	NULL
transfected	NULL
with	NULL
SFFV-human	NULL
Bc/-2	NULL
or	NULL
control	NULL
plasmid	NULL
SFFV-neo	NULL
.	NULL

Stably	NULL
transfected	NULL
Jurkat	NULL
cells	NULL
were	NULL
selected	NULL
in	NULL
G418	NULL
and	NULL
characterized	NULL
and	NULL
monitored	NULL
for	NULL
expression	NULL
of	NULL
human	NULL
BCL-2	NULL
protein	NULL
by	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
with	NULL
the	NULL
6C8	NULL
mAb	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
solid	NULL
phase	NULL
anti-human	NULL
CD3	NULL
mAb	NULL
(	NULL
HIT3a	NULL
,	NULL
PharMingen	NULL
)	NULL
and	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
10	NULL
ng/ml	NULL
(	NULL
Sigma	NULL
)	NULL
in	NULL
RPMI	NULL
1640	NULL
complete	NULL
media	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

Cell	NULL
Cycle	NULL
Analysis	NULL
.	NULL

Stimulated	NULL
T	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
twice	NULL
in	NULL
cold	NULL
PBS	NULL
,	NULL
and	NULL
lysed	NULL
in	NULL
Krishan	NULL
's	NULL
reagent	NULL
(	NULL
0.05	NULL
mg/ml	NULL
propidium	NULL
iodide/0.1	NULL
%	NULL
sodium	NULL
citrate/0.02	NULL
mg/ml	NULL
ribonuclease	NULL
A/0.3	NULL
%	NULL
Nonidet	NULL
P-40	NULL
)	NULL
.	NULL

Cell	NULL
nuclei	NULL
were	NULL
then	NULL
analyzed	NULL
at	NULL
low	NULL
flow	NULL
rate	NULL
for	NULL
DNA	NULL
content	NULL
based	NULL
on	NULL
FL-2A	NULL
versus	NULL
FL-2W	NULL
linear	NULL
plots	NULL
on	NULL
a	NULL
FACscan	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
using	NULL
CELLFIT	NULL
or	NULL
CELLQUEST	NULL
software	NULL
.	NULL

In	NULL
several	NULL
experiments	NULL
,	NULL
cell	NULL
cycle	NULL
analysis	NULL
of	NULL
S-phase	NULL
distribution	NULL
was	NULL
confirmed	NULL
with	NULL
BrdU	NULL
incorporation	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Reverse	NULL
Trascription-PCR	NULL
(	NULL
RT-PCR	NULL
)	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
activated	NULL
T	NULL
cells	NULL
using	NULL
the	NULL
acid	NULL
quanidium	NULL
thiocyanate	NULL
phenol-chloroform	NULL
extraction	NULL
method	NULL
(	NULL
RNAzol	NULL
)	NULL
.	NULL

One	NULL
micro-gram	NULL
RNA	NULL
was	NULL
reverse	NULL
transcribed	NULL
(	NULL
RT	NULL
Superscript	NULL
,	NULL
GIBCO	NULL
)	NULL
with	NULL
random	NULL
hexamers	NULL
to	NULL
generate	NULL
cDNA	NULL
(	NULL
20	NULL
wl	NULL
)	NULL
for	NULL
each	NULL
time	NULL
point	NULL
.	NULL

Two	NULL
microliters	NULL
of	NULL
each	NULL
cDNA	NULL
mixture	NULL
was	NULL
amplified	NULL
with	NULL
0.5	NULL
units	NULL
Taq	NULL
polymerase	NULL
(	NULL
Perkin-Elmer	NULL
)	NULL
using	NULL
specific	NULL
oligonucleotide	NULL
primers	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Preliminary	NULL
experiments	NULL
were	NULL
performed	NULL
to	NULL
determine	NULL
the	NULL
optimal	NULL
number	NULL
of	NULL
cycles	NULL
for	NULL
quantitative	NULL
determination	NULL
of	NULL
each	NULL
reaction	NULL
product	NULL
under	NULL
the	NULL
conditions	NULL
of	NULL
annealing	NULL
at	NULL
60°C	NULL
(	NULL
1	NULL
min	NULL
)	NULL
,	NULL
extension	NULL
at	NULL
72°C	NULL
(	NULL
1	NULL
min	NULL
)	NULL
,	NULL
and	NULL
denaturing	NULL
at	NULL
94°C	NULL
(	NULL
1	NULL
min	NULL
)	NULL
using	NULL
a	NULL
Perkin-Elmer	NULL
Thermocycler	NULL
.	NULL

One	NULL
tenth	NULL
of	NULL
each	NULL
reaction	NULL
mixture	NULL
was	NULL
electrophoresed	NULL
on	NULL
4-20	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
(	NULL
NOVEX	NULL
,	NULL
San	NULL
Diego	NULL
)	NULL
in	NULL
1	NULL
%	NULL
TBE	NULL
at	NULL
100	NULL
volts	NULL
;	NULL
RT-PCR	NULL
products	NULL
were	NULL
transferred	NULL
to	NULL
0.45	NULL
u	NULL
nylon	NULL
membrane	NULL
in	NULL
0.5	NULL
%	NULL
TBE	NULL
at	NULL
200	NULL
mA	NULL
for	NULL
1	NULL
hr	NULL
.	NULL

Nylon	NULL
membranes	NULL
were	NULL
probed	NULL
with	NULL
*P-end-labeled	NULL
internal	NULL
oligonucleotides	NULL
at	NULL
42°C	NULL
for	NULL
16-24	NULL
hr	NULL
.	NULL

Membranes	NULL
were	NULL
washed	NULL
and	NULL
exposed	NULL
in	NULL
the	NULL
linear	NULL
range	NULL
of	NULL
x-ray	NULL
film	NULL
(	NULL
Kodak	NULL
)	NULL
.	NULL

Electrophoretic	NULL
Mobility-Shift	NULL
Assay	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
5	NULL
X	NULL
10	NULL
``	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
solid	NULL
phase	NULL
and	NULL
20	NULL
ng/ml	NULL
PMA	NULL
in	NULL
T75	NULL
culture	NULL
flasks	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
the	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
.	NULL

Electrophoretic	NULL
mobility-shift	NULL
assay	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
done	NULL
with	NULL
2.5	NULL
ug	NULL
protein	NULL
in	NULL
the	NULL
10	NULL
mM	NULL
TrisHCI	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
5	NULL
%	NULL
glycerol	NULL
,	NULL
10	NULL
ug	NULL
BSA	NULL
,	NULL
and	NULL
1	NULL
ug	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
20	NULL
pl	NULL
.	NULL

The	NULL
binding	NULL
reactions	NULL
were	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
20	NULL
min	NULL
(	NULL
AP-1	NULL
)	NULL
or	NULL
30	NULL
min	NULL
[	NULL
NFAT	NULL
(	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
)	NULL
,	NULL
NFKB	NULL
,	NULL
OCT	NULL
with	NULL
0.2-0.4	NULL
ng	NULL
double-stranded	NULL
oligonucleotide	NULL
.	NULL

Gel-purified	NULL
double-stranded	NULL
oligonucleotides	NULL
were	NULL
end-labeled	NULL
with	NULL
[	NULL
y-	NULL
>	NULL
``	NULL
P	NULL
]	NULL
ATP	NULL
(	NULL
Amersham	NULL
)	NULL
using	NULL
T4	NULL
kinase	NULL
.	NULL

Oligonucleotides	NULL
for	NULL
human	NULL
NFAT	NULL
,	NULL
NFxB	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
OCT-1	NULL
(	NULL
28	NULL
,	NULL
29	NULL
)	NULL
containing	NULL
monomer	NULL
binding	NULL
sites	NULL
were	NULL
used	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
electrophoresed	NULL
in	NULL
native	NULL
6	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
in	NULL
0.5	NULL
%	NULL
TBE	NULL
at	NULL
100	NULL
V.	NULL
Confocal	NULL
Microscopy	NULL
.	NULL

Both	NULL
Jurkat/neo	NULL
and	NULL
Jurkat/Bcl-2	NULL
cells	NULL
were	NULL
fixed	NULL
and	NULL
permeabilized	NULL
with	NULL
4	NULL
%	NULL
paraformaldehyde	NULL
and	NULL
methanol	NULL
.	NULL

Anti-NFATc3	NULL
polyclonal	NULL
antibody	NULL
and	NULL
fluores-cein-conjugated	NULL
goat	NULL
anti-rabbit	NULL
IgG	NULL
were	NULL
used	NULL
to	NULL
stain	NULL
NFATc3	NULL
.	NULL

Nuclei	NULL
were	NULL
counterstained	NULL
by	NULL
propidium	NULL
iodide	NULL
.	NULL

Confocal	NULL
laser	NULL
scanning	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
Sarastro	NULL
2000	NULL
confocal	NULL
laser	NULL
scanning	NULL
microscope	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
)	NULL
and	NULL
IMMAGE	NULL
SPACE	NULL
software	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
Transient	NULL
Transfection	NULL
and	NULL
Luciferase	NULL
Assay	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
10	NULL
)	NULL
were	NULL
transiently	NULL
transfected	NULL
by	NULL
electroporation	NULL
(	NULL
960	NULL
uF	NULL
,	NULL
250	NULL
V	NULL
)	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
NFAT-luciferase	NULL
or	NULL
AP-1-luciferase	NULL
reporter	NULL
DNA	NULL
.	NULL

Eighteen	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
300	NULL
ng/ml	NULL
anti-CD3	NULL
plus	NULL
10	NULL
ng/ml	NULL
PMA	NULL
.	NULL

A	NULL
number	NULL
of	NULL
cells	NULL
(	NULL
10°	NULL
)	NULL
per	NULL
each	NULL
condition	NULL
were	NULL
harvested	NULL
at	NULL
6	NULL
br	NULL
after	NULL
activation	NULL
for	NULL
AP-1	NULL
or	NULL
24	NULL
hr	NULL
for	NULL
NFAT	NULL
reporter	NULL
constructs	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
(	NULL
Luciferase	NULL
Assay	NULL
System	NULL
,	NULL
Promega	NULL
)	NULL
.	NULL

RESULTS	NULL
BCL-2	NULL
Influences	NULL
Thymocyte	NULL
Cell	NULL
Cycle	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
effect	NULL
of	NULL
BCL-2	NULL
on	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
thymocytes	NULL
from	NULL
Bel-2~~	NULL
,	NULL
Bel-2*'~-	NULL
,	NULL
Bel-2*'*	NULL
,	NULL
and	NULL
Ick®	NULL
``	NULL
-Bcel-2	NULL
transgenic	NULL
mice	NULL
(	NULL
gf	NULL
)	NULL
were	NULL
pulsed	NULL
with	NULL
10	NULL
uM	NULL
BrdU	NULL
for	NULL
1	NULL
hr	NULL
at	NULL
37°	NULL
in	NULL
10	NULL
%	NULL
FCS	NULL
stained	NULL
with	NULL
anti-BrdU-fluorescein	NULL
isothiocyanate	NULL
and	NULL
counterstained	NULL
with	NULL
propidium	NULL
iodide	NULL
.	NULL

Similar	NULL
to	NULL
prior	NULL
studies	NULL
,	NULL
8.1	NULL
%	NULL
of	NULL
Bcel-2*'*	NULL
(	NULL
wild-type	NULL
)	NULL
thymocytes	NULL
were	NULL
in	NULL
S	NULL
phase	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

However	NULL
,	NULL
more	NULL
thymocytes	NULL
were	NULL
consistently	NULL
in	NULL
cycle	NULL
as	NULL
BCL-2	NULL
levels	NULL
fell	NULL
in	NULL
Bel-2*'~	NULL
and	NULL
Bel-2~~-	NULL
mice	NULL
9.1	NULL
%	NULL
and	NULL
9.5	NULL
%	NULL
,	NULL
respectively	NULL
,	NULL
in	NULL
the	NULL
examples	NULL
shown	NULL
here	NULL
.	NULL

Most	NULL
strikingly	NULL
,	NULL
overexpressed	NULL
BCL-2	NULL
resulted	NULL
in	NULL
a	NULL
marked	NULL
decrease	NULL
of	NULL
thymocytes	NULL
in	NULL
S	NULL
phase	NULL
,	NULL
only	NULL
1.5	NULL
%	NULL
in	NULL
the	NULL
Bc/-2	NULL
gf	NULL
mouse	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

BCL-2	NULL
Levels	NULL
Determine	NULL
Cell	NULL
Volume	NULL
of	NULL
Resting	NULL
T	NULL
Cells	NULL
.	NULL

Peripheral	NULL
T	NULL
cells	NULL
are	NULL
in	NULL
the	NULL
Go	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
before	NULL
activation	NULL
.	NULL

Cell	NULL
volume	NULL
represents	NULL
one	NULL
further	NULL
measurement	NULL
of	NULL
the	NULL
relative	NULL
state	NULL
of	NULL
quiescence	NULL
.	NULL

The	NULL
Bel-2~~-	NULL
,	NULL
Bel-2*'~	NULL
,	NULL
Bel-2+**	NULL
,	NULL
and	NULL
Bcl-2	NULL
gf	NULL
genotypes	NULL
displayed	NULL
stepwise	NULL
increments	NULL
of	NULL
BCL-2	NULL
protein	NULL
in	NULL
purified	NULL
splenic	NULL
T	NULL
cells	NULL
(	NULL
10	NULL
)	NULL
.	NULL

We	NULL
noted	NULL
that	NULL
BCL-2	NULL
levels	NULL
dictated	NULL
T	NULL
cell	NULL
size	NULL
as	NULL
measured	NULL
by	NULL
forward	NULL
scatter	NULL
(	NULL
linear	NULL
scale	NULL
)	NULL
on	NULL
flow	NULL
cytometry	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
shown	NULL
,	NULL
the	NULL
forward	NULL
scatter	NULL
of	NULL
Bel-2~~	NULL
cells	NULL
was	NULL
456	NULL
mean	NULL
channel	NULL
unites	NULL
,	NULL
while	NULL
the	NULL
forward	NULL
scatter	NULL
of	NULL
Bel-2*/*	NULL
T	NULL
cells	NULL
was	NULL
421	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
T	NULL
cells	NULL
from	NULL
Ick®P	NULL
``	NULL
-Bei-2	NULL
transgenic	NULL
mice	NULL
were	NULL
the	NULL
smallest	NULL
with	NULL
a	NULL
forward	NULL
scatter	NULL
of	NULL
336	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
cell	NULL
volume	NULL
was	NULL
determined	NULL
by	NULL
a	NULL
Coulter	NULL
Counter	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

BCL-2	NULL
Determines	NULL
the	NULL
Duration	NULL
of	NULL
G	NULL
,	NULL
-	NULL
>	NULL
S	NULL
Phase	NULL
.	NULL

T	NULL
cells	NULL
from	NULL
the	NULL
Bel-2	NULL
genetic	NULL
models	NULL
were	NULL
used	NULL
to	NULL
assess	NULL
the	NULL
role	NULL
of	NULL
BCL-2	NULL
upon	NULL
activation-induced	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

The	NULL
time	NULL
course	NULL
of	NULL
mitogenesis	NULL
as	NULL
measured	NULL
by	NULL
the	NULL
time	NULL
for	NULL
stimulated	NULL
T	NULL
cells	NULL
to	NULL
enter	NULL
S	NULL
phase	NULL
proved	NULL
proportional	NULL
to	NULL
the	NULL
level	NULL
of	NULL
BCL-2	NULL
.	NULL

Peripheral	NULL
T	NULL
cells	NULL
from	NULL
individual	NULL
mice	NULL
were	NULL
stimulated	NULL
with	NULL
plate	NULL
bound	NULL
(	NULL
solid	NULL
phase	NULL
)	NULL
anti-CD3	NULL
monoclo-nal	NULL
antibody	NULL
(	NULL
mAb	NULL
)	NULL
and	NULL
were	NULL
analyzed	NULL
for	NULL
DNA	NULL
content	NULL
by	NULL
propidium	NULL
iodide	NULL
staining	NULL
at	NULL
serial	NULL
time	NULL
points	NULL
.	NULL

Be/-2	NULL
gf	NULL
T	NULL
cells	NULL
showed	NULL
a	NULL
marked	NULL
delay	NULL
of	NULL
entry	NULL
into	NULL
S	NULL
phase	NULL
after	NULL
activation	NULL
when	NULL
compared	NULL
with	NULL
Bc/-2*/*	NULL
T	NULL
cells	NULL
.	NULL

Conversely	NULL
,	NULL
Bel-2~~-	NULL
T	NULL
cells	NULL
entered	NULL
S	NULL
phase	NULL
more	NULL
rapidly	NULL
than	NULL
normal	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
at	NULL
24	NULL
hr	NULL
postactivation	NULL
,	NULL
32	NULL
%	NULL
of	NULL
Bel-2~~	NULL
,	NULL
22	NULL
%	NULL
of	NULL
Bcl-2*~	NULL
,	NULL
9	NULL
%	NULL
of	NULL
Bel-2*'*	NULL
,	NULL
but	NULL
only	NULL
3	NULL
%	NULL
of	NULL
Bel-2	NULL
gf	NULL
T	NULL
cells	NULL
were	NULL
in	NULL
S	NULL
+	NULL
G	NULL
;	NULL
/M	NULL
phase	NULL
based	NULL
upon	NULL
>	NULL
2N	NULL
DNA	NULL
content	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
Be/-2	NULL
could	NULL
still	NULL
regulate	NULL
cells	NULL
activated	NULL
through	NULL
multiple	NULL
signal	NULL
transduction	NULL
pathways	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
costimu-lated	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
as	NULL
well	NULL
as	NULL
with	NULL
anti-CD3	NULL
.	NULL

As	NULL
previously	NULL
noted	NULL
,	NULL
addition	NULL
of	NULL
anti-CD28	NULL
mAb	NULL
to	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
optimal	NULL
concentrations	NULL
of	NULL
anti-CD3	NULL
has	NULL
a	NULL
small	NULL
,	NULL
additional	NULL
affect	NULL
on	NULL
cell	NULL
cycle	NULL
progression	NULL
(	NULL
30	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

At	NULL
24	NULL
hr	NULL
postactivation	NULL
,	NULL
35	NULL
%	NULL
of	NULL
Bel-2~~	NULL
,	NULL
27	NULL
%	NULL
of	NULL
Bel-2*	NULL
!	NULL

~	NULL
,	NULL
15	NULL
%	NULL
of	NULL
Bel-2*'*	NULL
,	NULL
and	NULL
yet	NULL
only	NULL
6	NULL
%	NULL
of	NULL
Bcl-2	NULL
gf	NULL
T	NULL
cells	NULL
were	NULL
determined	NULL
to	NULL
be	NULL
in	NULL
S	NULL
+	NULL
G	NULL
;	NULL
/M	NULL
.	NULL

Thus	NULL
,	NULL
BCL-2	NULL
had	NULL
a	NULL
similar	NULL
affect	NULL
upon	NULL
the	NULL
kinetics	NULL
of	NULL
Go	NULL
-	NULL
>	NULL
S	NULL
phase	NULL
transition	NULL
following	NULL
costimulation	NULL
.	NULL

BCL-2	NULL
Also	NULL
Affects	NULL
Activation	NULL
Induced	NULL
Cell	NULL
Death	NULL
.	NULL

Forty-eight	NULL
hours	NULL
after	NULL
stimulation	NULL
,	NULL
the	NULL
percent	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
+	NULL
G	NULL
;	NULL
/M	NULL
phases	NULL
decreased	NULL
in	NULL
Bc/-2-deficient	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
was	NULL
still	NULL
increasing	NULL
in	NULL
T	NULL
cells	NULL
overexpressing	NULL
Bel-2	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
4	NULL
and	NULL
B	NULL
)	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
there	NULL
may	NULL
be	NULL
differences	NULL
in	NULL
viability	NULL
that	NULL
follow	NULL
activation	NULL
.	NULL

To	NULL
evaluate	NULL
this	NULL
,	NULL
T	NULL
cells	NULL
that	NULL
were	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
were	NULL
assessed	NULL
for	NULL
apoptotic	NULL
cells	NULL
,	NULL
which	NULL
reside	NULL
in	NULL
the	NULL
population	NULL
with	NULL
<	NULL
2N	NULL
DNA	NULL
content	NULL
.	NULL

Immediately	NULL
after	NULL
Cell	NULL
Biology	NULL
:	NULL
Linette	NULL
et	NULL
al	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
9547	NULL
A	NULL
Bcl-2	NULL
-/-	NULL
Bcl-2	NULL
+/-hang	NULL
cit	NULL
_	NULL
,	NULL
87.5/9.5/3.0	NULL
{	NULL
eas	NULL
V	NULL
...	NULL
..	NULL
88.8/9.1/2.1	NULL
3	NULL
6905.3	NULL
:	NULL
e	NULL
}	NULL
ca	NULL
]	NULL
5	NULL
aim—j	NULL
~|	NULL
{	NULL
-	NULL
#	NULL
°	NULL
a	NULL
``	NULL
``	NULL
='ay	NULL
'	NULL
``	NULL
;	NULL
n	NULL
;	NULL
”	NULL
'='=a	NULL
``	NULL
T2dad	NULL
``	NULL
Bcl-2	NULL
+/+	NULL
IckP	NULL
``	NULL
-Bci-2	NULL
mawr	NULL
©'89.1/8.1/2.8	NULL
lage	NULL
96.5/1.5/2.0	NULL
D	NULL
com	NULL
~	NULL
sam	NULL
~	NULL
B	NULL
1	NULL
:	NULL
co	NULL
i	NULL
E	NULL
6	NULL
499	NULL
9g	NULL
CED	NULL
;	NULL
3	NULL
+	NULL
-	NULL
ﬁ	NULL
b	NULL
*	NULL
Tg	NULL
Ulan	NULL
leo	NULL
tea	NULL
Cee	NULL
O	NULL
``	NULL
'	NULL
a	NULL
~~	NULL
see	NULL
cep	NULL
teo	NULL
``	NULL
'see	NULL
Sines	NULL
PROPIDIUM	NULL
I0DIDE	NULL
PROPIDIUM	NULL
10DIDE	NULL
B	NULL
100	NULL
|	NULL
belg	NULL
+/+	NULL
-	NULL
$	NULL
i	NULL
1	NULL
(	NULL
421	NULL
)	NULL
``	NULL
=	NULL
{	NULL
&	NULL
so	NULL
-	NULL
a	NULL
1	NULL
Ick	NULL
``	NULL
60	NULL
{	NULL
=	NULL
4	NULL
§	NULL
-	NULL
]	NULL
0	NULL
4	NULL
o	NULL
40	NULL
2	NULL
(	NULL
456	NULL
)	NULL
mean	NULL
channel	NULL
no	NULL
.	NULL

20	NULL
-0-	NULL
T	NULL
--	NULL
T	NULL
-r	NULL
T	NULL
``	NULL
4	NULL
,	NULL
©	NULL
4	NULL
0	NULL
200	NULL
400	NULL
600	NULL
800	NULL
1000	NULL
FSC-H	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

BCL-2	NULL
affects	NULL
cell	NULL
cycle	NULL
and	NULL
cell	NULL
size	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Thymocytes	NULL
from	NULL
healthy	NULL
5-week-old	NULL
Bel-2~~	NULL
,	NULL
Bel-2*'~	NULL
,	NULL
and	NULL
Bcl-2*'*	NULL
littermates	NULL
as	NULL
well	NULL
as	NULL
an	NULL
IckP	NULL
``	NULL
-Bei-2	NULL
transgenic	NULL
mouse	NULL
were	NULL
incubated	NULL
with	NULL
BrdU	NULL
,	NULL
washed	NULL
and	NULL
developed	NULL
with	NULL
an	NULL
anti-BrdU-FITC	NULL
antibody	NULL
.	NULL

Propidium	NULL
iodide	NULL
staining	NULL
was	NULL
performed	NULL
just	NULL
before	NULL
analysis	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
Cells	NULL
in	NULL
Go	NULL
+	NULL
G1/S/G	NULL
;	NULL
+	NULL
M	NULL
phase	NULL
is	NULL
shown	NULL
in	NULL
the	NULL
upper	NULL
right	NULL
corner	NULL
of	NULL
each	NULL
dot	NULL
plot	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
mean	NULL
forward	NULL
scatter	NULL
(	NULL
linear	NULL
scale	NULL
)	NULL
of	NULL
CD3	NULL
positive	NULL
T	NULL
cells	NULL
from	NULL
each	NULL
mouse	NULL
(	NULL
7	NULL
weeks	NULL
of	NULL
age	NULL
)	NULL
was	NULL
determined	NULL
on	NULL
a	NULL
FACscan	NULL
with	NULL
CELLQUEST	NULL
software	NULL
.	NULL

Purified	NULL
splenic	NULL
T	NULL
cells	NULL
were	NULL
>	NULL
95	NULL
%	NULL
CD3	NULL
positive	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
experiments	NULL
.	NULL

purification	NULL
,	NULL
less	NULL
than	NULL
1	NULL
%	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
each	NULL
mouse	NULL
(	NULL
Be/-2~~-	NULL
,	NULL
7	NULL
%	NULL
of	NULL
Bel-2	NULL
gf	NULL
T	NULL
cells	NULL
were	NULL
apoptotic	NULL
.	NULL

Bel-2~~	NULL
cells	NULL
continued	NULL
Bel-2*'*	NULL
,	NULL
and	NULL
Bel-2	NULL
gf	NULL
)	NULL
were	NULL
apoptotic	NULL
.	NULL

After	NULL
anti-CD3	NULL
acti-	NULL
to	NULL
show	NULL
an	NULL
increased	NULL
percentage	NULL
of	NULL
dying	NULL
(	NULL
17	NULL
%	NULL
)	NULL
as	NULL
well	NULL
as	NULL
vation	NULL
,	NULL
Bel-2~~-	NULL
T	NULL
cells	NULL
demonstrated	NULL
accelerated	NULL
cell	NULL
death	NULL
as	NULL
proliferating	NULL
cells	NULL
(	NULL
33	NULL
%	NULL
)	NULL
at	NULL
36	NULL
hr	NULL
.	NULL

Even	NULL
after	NULL
48	NULL
hr	NULL
,	NULL
most	NULL
Bel-2	NULL
well	NULL
as	NULL
premature	NULL
cell	NULL
cycle	NULL
progression	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

For	NULL
exam-	NULL
gf	NULL
T	NULL
cells	NULL
remained	NULL
in	NULL
with	NULL
only	NULL
8	NULL
%	NULL
apoptotic	NULL
and	NULL
15	NULL
%	NULL
ple	NULL
,	NULL
at	NULL
24	NULL
hr	NULL
,	NULL
27	NULL
%	NULL
of	NULL
Bel-2-'~-	NULL
versus	NULL
12	NULL
%	NULL
of	NULL
Bel-2*'*	NULL
,	NULL
but	NULL
only	NULL
proliferating	NULL
cells	NULL
.	NULL

These	NULL
differential	NULL
results	NULL
were	NULL
confirmed	NULL
by	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
9548	NULL
Cell	NULL
Biology	NULL
:	NULL
Linette	NULL
et	NULL
al	NULL
.	NULL

50	NULL
-o-	NULL
bel2	NULL
-/-A	NULL
|	NULL
-	NULL
#	NULL
-	NULL
bol	NULL
?	NULL

+/-	NULL
B	NULL
-0-	NULL
bol2	NULL
+/+	NULL
=-4-	NULL
IckP	NULL
``	NULL
-bel2	NULL
a=	NULL
a	NULL
>	NULL
a	NULL
o	NULL
a	NULL
o	NULL
L	NULL
9	NULL
8	NULL
e	NULL
D	NULL
``	NULL
a.	NULL
IP	NULL
'	NULL
a	NULL
$	NULL
&	NULL
0	NULL
4	NULL
--	NULL
--	NULL
--	NULL
t	NULL
--	NULL
+	NULL
--	NULL
--	NULL
~-+	NULL
--	NULL
~~-+-	NULL
0	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
70	NULL
80	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
70	NULL
80	NULL
Hours	NULL
Hours	NULL
C	NULL
TIME	NULL
0	NULL
16	NULL
hr	NULL
24	NULL
hr	NULL
36	NULL
hr	NULL
48hr	NULL
L	NULL
E	NULL
4	NULL
4	NULL
tog	NULL
e	NULL
3	NULL
3	NULL
(	NULL
%	NULL
<	NULL
2n	NULL
)	NULL
,	NULL
(	NULL
%	NULL
5+62M	NULL
)	NULL
[	NULL
s	NULL
2	NULL
3	NULL
S	NULL
&	NULL
j	NULL
07	NULL
0.61	NULL
&	NULL
js	NULL
21	NULL
27	NULL
18	NULL
17	NULL
33	NULL
co	NULL
E	NULL
4	NULL
o	NULL
4	NULL
7	NULL
y	NULL
o	NULL
0	NULL
o	NULL
0	NULL
1000	NULL
0	NULL
1000	NULL
0	NULL
1000	NULL
0	NULL
1000	NULL
8	NULL
8	NULL
8	NULL
&	NULL
t	NULL
f	NULL
<	NULL
I	NULL
``	NULL
<	NULL
8	NULL
{	NULL
os	NULL
0.6	NULL
i	NULL
n	NULL
1.1	NULL
12	NULL
8.6	NULL
112	NULL
24	NULL
112	NULL
al	NULL
co	NULL
o	NULL
4	NULL
o	NULL
4	NULL
o	NULL
4	NULL
o	NULL
O	NULL
:	NULL
0	NULL
1000	NULL
0	NULL
1000	NULL
0	NULL
1000	NULL
0	NULL
1000	NULL
0	NULL
1000	NULL
§	NULL
8	NULL
g	NULL
a	NULL
a	NULL
S	NULL
:	NULL
G	NULL
G	NULL
I	NULL
N-	NULL
N-€	NULL
g	NULL
4	NULL
E	NULL
E	NULL
G	NULL
G	NULL
y	NULL
'	NULL
§	NULL
103	NULL
2.7	NULL
i	NULL
5	NULL
2.4	NULL
3	NULL
7	NULL
3.8	NULL
17	NULL
8.4	NULL
is	NULL
15	NULL
-	NULL
o	NULL
4	NULL
~£	NULL
O	NULL
:	NULL
O	NULL
:	NULL
O-0	NULL
1000	NULL
0	NULL
~	NULL
FL2A	NULL
FL2-A	NULL
100	NULL
°	NULL
FL2-A	NULL
10°	NULL
°	NULL
FL2-A	NULL
108°	NULL
°	NULL
FL2-A	NULL
1000	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

BCL-2	NULL
regulates	NULL
the	NULL
Go	NULL
-	NULL
>	NULL
S	NULL
transition	NULL
.	NULL

Purified	NULL
T	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
500	NULL
ng	NULL
per	NULL
well	NULL
solid	NULL
phase	NULL
)	NULL
(	NULL
4	NULL
)	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
PV-1	NULL
(	NULL
5	NULL
ug/ml	NULL
fluid	NULL
phase	NULL
added	NULL
at	NULL
time	NULL
0	NULL
)	NULL
(	NULL
B	NULL
)	NULL
.	NULL

At	NULL
serial	NULL
time	NULL
points	NULL
,	NULL
cells	NULL
from	NULL
individual	NULL
wells	NULL
were	NULL
harvested	NULL
and	NULL
analyzed	NULL
for	NULL
DNA	NULL
content	NULL
after	NULL
gating	NULL
out	NULL
apoptotic	NULL
cells	NULL
(	NULL
<	NULL
2N	NULL
DNA	NULL
content	NULL
)	NULL
and	NULL
debris	NULL
.	NULL

A	NULL
total	NULL
of	NULL
10,000	NULL
events	NULL
were	NULL
collected	NULL
and	NULL
cells	NULL
with	NULL
>	NULL
2N	NULL
DNA	NULL
content	NULL
were	NULL
determined	NULL
to	NULL
be	NULL
in	NULL
S	NULL
+	NULL
G	NULL
;	NULL
/M	NULL
phase	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
10	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Purified	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
were	NULL
studied	NULL
for	NULL
DNA	NULL
content	NULL
by	NULL
propidium	NULL
iodide	NULL
staining	NULL
and	NULL
flow	NULL
cytometry	NULL
.	NULL

Only	NULL
small	NULL
debris	NULL
was	NULL
gated	NULL
out	NULL
,	NULL
such	NULL
that	NULL
apoptotic	NULL
nuclei	NULL
were	NULL
also	NULL
included	NULL
in	NULL
this	NULL
analysis	NULL
.	NULL

The	NULL
percent	NULL
apoptotic	NULL
(	NULL
<	NULL
2N	NULL
)	NULL
and	NULL
proliferating	NULL
cells	NULL
(	NULL
>	NULL
2N	NULL
:	NULL
$	NULL
+	NULL
G	NULL
;	NULL
/M	NULL
)	NULL
is	NULL
indicated	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

TUNEL	NULL
(	NULL
TdT-mediated	NULL
dUTP-biotin	NULL
nick	NULL
end	NULL
labeling	NULL
)	NULL
(	NULL
31	NULL
)	NULL
,	NULL
which	NULL
proved	NULL
more	NULL
sensitive	NULL
than	NULL
propidium	NULL
iodide	NULL
in	NULL
detecting	NULL
apoptotic	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Regulation	NULL
of	NULL
p27*	NULL
``	NULL
``	NULL
but	NULL
Not	NULL
p21	NULL
Is	NULL
Altered	NULL
by	NULL
BCL-2	NULL
.	NULL

The	NULL
retarded	NULL
entry	NULL
of	NULL
Bcei-2	NULL
gf	NULL
T	NULL
cells	NULL
into	NULL
S	NULL
phase	NULL
was	NULL
accompanied	NULL
by	NULL
a	NULL
delayed	NULL
pattern	NULL
of	NULL
retinoblastoma	NULL
hyperphosphorylation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
prominence	NULL
of	NULL
underphosphorylated	NULL
Rb	NULL
was	NULL
also	NULL
recently	NULL
noted	NULL
in	NULL
Bel-2	NULL
gf	NULL
thymocytes	NULL
(	NULL
32	NULL
)	NULL
.	NULL

p27P	NULL
!	NULL

(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
and	NULL
p21	NULL
(	NULL
also	NULL
known	NULL
as	NULL
cip1	NULL
,	NULL
sdi	NULL
,	NULL
waf1	NULL
,	NULL
and	NULL
cap20	NULL
)	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
are	NULL
cyclin-dependent	NULL
kinase	NULL
(	NULL
cdk	NULL
)	NULL
inhibitors	NULL
present	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
resting	NULL
mature	NULL
T	NULL
cells	NULL
,	NULL
is	NULL
present	NULL
at	NULL
significant	NULL
levels	NULL
.	NULL

Upon	NULL
activation	NULL
,	NULL
p27	NULL
protein	NULL
is	NULL
degraded	NULL
during	NULL
early-to-mid	NULL
G	NULL
;	NULL
phase	NULL
,	NULL
presumably	NULL
mediated	NULL
by	NULL
IL-2	NULL
signaling	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
.	NULL

Conversely	NULL
,	NULL
resting	NULL
T	NULL
cells	NULL
possess	NULL
minimal	NULL
amounts	NULL
of	NULL
p21	NULL
,	NULL
but	NULL
upon	NULL
activation	NULL
p21	NULL
levels	NULL
increase	NULL
in	NULL
G1	NULL
.	NULL

Be/-2*/~	NULL
T	NULL
cells	NULL
show	NULL
an	NULL
accelerated	NULL
disappearance	NULL
of	NULL
p27P	NULL
``	NULL
protein	NULL
after	NULL
anti-CD3	NULL
activation	NULL
,	NULL
relative	NULL
to	NULL
Bce/-2t/'*	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

This	NULL
contrasts	NULL
with	NULL
a	NULL
delayed	NULL
loss	NULL
of	NULL
p27*P	NULL
``	NULL
in	NULL
Bel-2	NULL
gf	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
Cell	NULL
Biology	NULL
:	NULL
Linette	NULL
et	NULL
al	NULL
.	NULL

[	NULL
927mpl	NULL
p2l	NULL
Time	NULL
:	NULL
O	NULL
3	NULL
6	NULL
9	NULL
12	NULL
15	NULL
18	NULL
21	NULL
24	NULL
0	NULL
3	NULL
6	NULL
9	NULL
12	NULL
24	NULL
bcl2+/-	NULL
®ee	NULL
«	NULL
~-	NULL
W-	NULL
CMB	NULL
sme	NULL
ace	NULL
awe	NULL
bel	NULL
2	NULL
+/+	NULL
|	NULL
=	NULL
«	NULL
m	NULL
»	NULL
w	NULL
«	NULL
-	NULL
as	NULL
cue	NULL
cum	NULL
ame	NULL
Ick	NULL
``	NULL
-	NULL
bel2	NULL
-	NULL
®=	NULL
@	NULL
a	NULL
»	NULL
as	NULL
ae	NULL
__	NULL
~~	NULL
wan	NULL
can	NULL
cme	NULL
aut	NULL
th	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

-	NULL
p27°P	NULL
``	NULL
but	NULL
not	NULL
p21	NULL
levels	NULL
are	NULL
affected	NULL
by	NULL
BCL-2	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
p27©P	NULL
``	NULL
and	NULL
p21	NULL
in	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
500	NULL
ng	NULL
per	NULL
well	NULL
solid	NULL
phase	NULL
)	NULL
at	NULL
serial	NULL
time	NULL
points	NULL
.	NULL

Protein	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
in	NULL
each	NULL
lane	NULL
was	NULL
run	NULL
on	NULL
SDS/12	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
,	NULL
and	NULL
blotted	NULL
either	NULL
with	NULL
a	NULL
polyclonal	NULL
rabbit	NULL
anti-p27	NULL
Ab	NULL
(	NULL
Santa	NULL
Cruz	NULL
1	NULL
ug/tl	NULL
)	NULL
or	NULL
with	NULL
a	NULL
mAb	NULL
to	NULL
p21	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
J	NULL
.	NULL

Wade	NULL
Harper	NULL
,	NULL
Baylor	NULL
College	NULL
of	NULL
Medicine	NULL
)	NULL
.	NULL

Blots	NULL
were	NULL
developed	NULL
with	NULL
Enhanced	NULL
Chemiluminesence	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

The	NULL
p27	NULL
``	NULL
results	NULL
have	NULL
been	NULL
confirmed	NULL
in	NULL
two	NULL
additional	NULL
experiments	NULL
.	NULL

relative	NULL
amounts	NULL
of	NULL
in	NULL
T	NULL
cells	NULL
of	NULL
each	NULL
Bel-2	NULL
genotype	NULL
correlates	NULL
well	NULL
with	NULL
the	NULL
duration	NULL
of	NULL
the	NULL
Gy	NULL
-	NULL
>	NULL
S	NULL
phase	NULL
transition	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
BCL-2	NULL
had	NULL
no	NULL
striking	NULL
effect	NULL
upon	NULL
the	NULL
regulation	NULL
of	NULL
p21	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Proximal	NULL
Signal	NULL
Transduction	NULL
and	NULL
Immediate	NULL
Early	NULL
Gene	NULL
Responses	NULL
Appear	NULL
Unaffected	NULL
by	NULL
BCL-2	NULL
.	NULL

The	NULL
level	NULL
of	NULL
cell	NULL
surface	NULL
TCR/CD3	NULL
complex	NULL
did	NULL
not	NULL
vary	NULL
among	NULL
the	NULL
T	NULL
cells	NULL
of	NULL
various	NULL
Bcl-2	NULL
genotypes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
indicated	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
BCL-2	NULL
upon	NULL
T	NULL
cell	NULL
activation	NULL
would	NULL
reside	NULL
between	NULL
proximal	NULL
signal	NULL
transduction	NULL
events	NULL
and	NULL
distal	NULL
cell	NULL
cycle	NULL
machinery	NULL
.	NULL

Dissection	NULL
of	NULL
this	NULL
pathway	NULL
revealed	NULL
that	NULL
the	NULL
pattern	NULL
of	NULL
tyrosine	NULL
phosphorylated	NULL
proteins	NULL
was	NULL
similar	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
of	NULL
the	NULL
various	NULL
Bcl-2	NULL
genotypes	NULL
.	NULL

Similarly	NULL
,	NULL
the	NULL
rise	NULL
in	NULL
intracellular	NULL
ionized	NULL
calcium	NULL
concentrations	NULL
following	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
or	NULL
thymocytes	NULL
was	NULL
comparable	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
time	NULL
course	NULL
of	NULL
immediate	NULL
early	NULL
gene	NULL
induction	NULL
in	NULL
response	NULL
to	NULL
TCR/CD3	NULL
activation	NULL
was	NULL
assessed	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
c-Myc	NULL
RNA	NULL
was	NULL
detectable	NULL
at	NULL
30	NULL
min	NULL
postactivation	NULL
and	NULL
remained	NULL
elevated	NULL
at	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
6	NULL
hr	NULL
in	NULL
T	NULL
cells	NULL
of	NULL
all	NULL
four	NULL
Be/-2	NULL
genotypes	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

Other	NULL
immediate	NULL
early	NULL
genes	NULL
(	NULL
c-Fos	NULL
,	NULL
c-Jun	NULL
,	NULL
NGFI-B	NULL
)	NULL
were	NULL
also	NULL
induced	NULL
to	NULL
a	NULL
similar	NULL
degree	NULL
in	NULL
each	NULL
Bcl-2	NULL
genotype	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
proximal	NULL
signal	NULL
transduction	NULL
events	NULL
through	NULL
immediate	NULL
early	NULL
gene	NULL
transcription	NULL
were	NULL
not	NULL
strongly	NULL
influenced	NULL
by	NULL
BCL-2	NULL
.	NULL

BCL-2	NULL
Regulates	NULL
IL-2	NULL
Production	NULL
by	NULL
Activated	NULL
T	NULL
Cells	NULL
.	NULL

Most	NULL
cytokines	NULL
produced	NULL
by	NULL
T	NULL
cells	NULL
,	NULL
including	NULL
IL-2	NULL
,	NULL
display	NULL
a	NULL
temporal	NULL
time	NULL
course	NULL
typical	NULL
of	NULL
delayed	NULL
early	NULL
response	NULL
genes	NULL
.	NULL

IL-2	NULL
is	NULL
produced	NULL
by	NULL
activated	NULL
T	NULL
cells	NULL
and	NULL
acts	NULL
as	NULL
the	NULL
primary	NULL
progression	NULL
factor	NULL
in	NULL
mid	NULL
G	NULL
,	NULL
phase	NULL
for	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

Be/-2	NULL
gf	NULL
T	NULL
cells	NULL
produced	NULL
substantially	NULL
less	NULL
(	NULL
~5-fold	NULL
)	NULL
IL-2	NULL
compared	NULL
with	NULL
Bci-2**	NULL
T	NULL
cells	NULL
at	NULL
optimal	NULL
concentrations	NULL
of	NULL
anti-CD3	NULL
antibody	NULL
,	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
100	NULL
and	NULL
1000	NULL
ng	NULL
per	NULL
well	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
)	NULL
.	NULL

Of	NULL
interest	NULL
,	NULL
Bel-2*'~	NULL
and	NULL
Bcl-2-/-	NULL
T	NULL
cells	NULL
produced	NULL
greater	NULL
amounts	NULL
of	NULL
IL-2	NULL
and	NULL
even	NULL
produced	NULL
IL-2	NULL
following	NULL
suboptimal	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
10	NULL
ng	NULL
per	NULL
well	NULL
)	NULL
concentrations	NULL
of	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
)	NULL
.	NULL

Costimulation	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
as	NULL
well	NULL
as	NULL
anti-CD3	NULL
mAb	NULL
can	NULL
enhance	NULL
IL-2	NULL
production	NULL
(	NULL
as	NULL
well	NULL
as	NULL
other	NULL
cytokines	NULL
)	NULL
(	NULL
30	NULL
)	NULL
.	NULL

When	NULL
T	NULL
cells	NULL
from	NULL
all	NULL
groups	NULL
were	NULL
activated	NULL
with	NULL
an	NULL
optimal	NULL
concentration	NULL
(	NULL
1000	NULL
ng	NULL
per	NULL
well	NULL
)	NULL
of	NULL
anti-CD3	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
anti-CD28	NULL
mAb	NULL
produced	NULL
approximately	NULL
4-	NULL
to	NULL
S5-fold	NULL
more	NULL
IL-2	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

However	NULL
,	NULL
increasing	NULL
amounts	NULL
of	NULL
BCL-2	NULL
protein	NULL
proportionally	NULL
depressed	NULL
the	NULL
IL-2	NULL
response	NULL
to	NULL
costimulation	NULL
as	NULL
well	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
the	NULL
influence	NULL
of	NULL
BCL-2	NULL
operated	NULL
at	NULL
the	NULL
level	NULL
of	NULL
cytokine	NULL
transcription	NULL
,	NULL
RT-PCR	NULL
analysis	NULL
of	NULL
ZL-2	NULL
and	NULL
two	NULL
other	NULL
T	NULL
cell-derived	NULL
cytokines	NULL
,	NULL
IL-3	NULL
and	NULL
GM-CSF	NULL
,	NULL
was	NULL
performed	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
and	NULL
GM-CSF	NULL
RNA	NULL
was	NULL
quite	NULL
delayed	NULL
in	NULL
Bcl-2	NULL
gf	NULL
T	NULL
cells	NULL
when	NULL
compared	NULL
with	NULL
Bcel-2*'*	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
data	NULL
in	NULL
Fig	NULL
.	NULL

54	NULL
,	NULL
Bel-2~~	NULL
T	NULL
cells	NULL
showed	NULL
accelerated	NULL
transcription	NULL
of	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
and	NULL
GM-CSF	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

BCL-2	NULL
but	NULL
Not	NULL
Cysteine	NULL
Protease	NULL
Inhibitors	NULL
Block	NULL
Cytokine	NULL
Production	NULL
in	NULL
Jurkat	NULL
T	NULL
Cells	NULL
.	NULL

To	NULL
further	NULL
examine	NULL
the	NULL
interrelationship	NULL
amongst	NULL
BCL-2	NULL
,	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
and	NULL
IL-2	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
9549	NULL
A	NULL
bel-2	NULL
/-	NULL
bel-2	NULL
«	NULL
/-	NULL
lime	NULL
0	NULL
1/2	NULL
1	NULL
2	NULL
6	NULL
0	NULL
1/2	NULL
1	NULL
2	NULL
6	NULL
(	NULL
hours	NULL
)	NULL
bol-2	NULL
«	NULL
/+	NULL
IckP	NULL
``	NULL
-bet-2	NULL
B	NULL
IL-2	NULL
IL-3	NULL
GM-CSF	NULL
B-Actin	NULL
ime	NULL
0	NULL
1	NULL
2	NULL
6	NULL
m	NULL
0	NULL
1	NULL
2	NULL
6	NULL
2M	NULL
0	NULL
1	NULL
2	NULL
6	NULL
24	NULL
0	NULL
1	NULL
20	NULL
6	NULL
24	NULL
(	NULL
hours	NULL
)	NULL
pota	NULL
si-	NULL
«	NULL
-a	NULL
»	NULL
e	NULL
»	NULL
p	NULL
e	NULL
e	NULL
e	NULL
bot-2	NULL
+/+	NULL
w-	NULL
was	NULL
aap	NULL
®	NULL
w-	NULL
o	NULL
id	NULL
wo	NULL
m	NULL
K.	NULL
»	NULL
|	NULL
mmc	NULL
was	NULL
sew	NULL
mer	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

-	NULL
Bcl-2	NULL
alters	NULL
cytokine	NULL
RNA	NULL
induction	NULL
but	NULL
not	NULL
immediate	NULL
early	NULL
genes	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Induction	NULL
of	NULL
c-myc	NULL
in	NULL
T	NULL
cells	NULL
is	NULL
unaffected	NULL
by	NULL
BCL-2	NULL
.	NULL

Purified	NULL
T	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
activated	NULL
with	NULL
anti-CD3	NULL
(	NULL
500	NULL
ng	NULL
per	NULL
well	NULL
solid	NULL
phase	NULL
)	NULL
for	NULL
0.5	NULL
,	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
6	NULL
hr	NULL
,	NULL
and	NULL
total	NULL
RNA	NULL
was	NULL
isolated	NULL
.	NULL

Products	NULL
of	NULL
a	NULL
quantitative	NULL
RT-PCR	NULL
assay	NULL
were	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
and	NULL
hybridized	NULL
with	NULL
a	NULL
*°P-radiolabeled	NULL
mouse	NULL
c-Myc	NULL
fragment	NULL
.	NULL

RT-PCR	NULL
of	NULL
B-actin	NULL
confirmed	NULL
that	NULL
comparable	NULL
amounts	NULL
of	NULL
RNA	NULL
were	NULL
present	NULL
in	NULL
each	NULL
sample	NULL
(	NULL
B	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Cytokine	NULL
RNA	NULL
induction	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
is	NULL
modulated	NULL
by	NULL
BCL-2	NULL
.	NULL

RNA	NULL
samples	NULL
from	NULL
A	NULL
were	NULL
assessed	NULL
by	NULL
quantitative	NULL
RT-PCR	NULL
using	NULL
oligonucleotide	NULL
primers	NULL
for	NULL
murine	NULL
IL-2	NULL
(	NULL
28	NULL
cycles	NULL
)	NULL
,	NULL
IL-3	NULL
(	NULL
32	NULL
cycles	NULL
)	NULL
,	NULL
GM-CSF	NULL
(	NULL
32	NULL
cycles	NULL
)	NULL
,	NULL
and	NULL
B-actin	NULL
(	NULL
24	NULL
cycles	NULL
)	NULL
.	NULL

PCR	NULL
products	NULL
were	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
and	NULL
hybridized	NULL
with	NULL
a	NULL
*	NULL
%	NULL
P-end-labeled	NULL
oligonucleotide	NULL
probe	NULL
internal	NULL
to	NULL
each	NULL
set	NULL
of	NULL
primers	NULL
.	NULL

This	NULL
result	NULL
is	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

transcription	NULL
,	NULL
a	NULL
T	NULL
cell	NULL
line	NULL
model	NULL
was	NULL
established	NULL
.	NULL

Jurkat	NULL
is	NULL
a	NULL
well-characterized	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
line	NULL
used	NULL
principally	NULL
to	NULL
study	NULL
activation	NULL
events	NULL
and	NULL
IL-2	NULL
regulation	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
stably	NULL
transfected	NULL
with	NULL
Bc/-2	NULL
and	NULL
expressed	NULL
~10-fold	NULL
20	NULL
30	NULL
-	NULL
€	NULL
e	NULL
I/	NULL
Ill	NULL
anti-CD3	NULL
-	NULL
#	NULL
-	NULL
+/	NULL
.	NULL

f	NULL
,	NULL
``	NULL
A.	NULL
g-	NULL
+/+	NULL
B	NULL
.	NULL

-t-	NULL
lokP	NULL
``	NULL
bol2	NULL
§	NULL
€	NULL
2	NULL
10	NULL
-	NULL
G	NULL
Y	NULL
a	NULL
r	NULL
a	NULL
o	NULL
//	NULL
T	NULL
T	NULL
T	NULL
T	NULL
A4	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
«	NULL
f-	NULL
+	NULL
]	NULL
-anti-CD3	NULL
(	NULL
ng/well	NULL
)	NULL
+/+	NULL
-	NULL
Ick	NULL
``	NULL
-bol2	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

BCL-2	NULL
regulates	NULL
IL-2	NULL
production	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Purified	NULL
T	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
plates	NULL
coated	NULL
with	NULL
10-fold	NULL
dilutions	NULL
of	NULL
anti-CD3	NULL
mAb	NULL
.	NULL

After	NULL
24	NULL
hr	NULL
,	NULL
cell-free	NULL
supernatants	NULL
were	NULL
assayed	NULL
for	NULL
murine	NULL
IL-2	NULL
using	NULL
a	NULL
capture	NULL
ELISA	NULL
with	NULL
mAb	NULL
pairs	NULL
(	NULL
PharM-ingen	NULL
)	NULL
.	NULL

Each	NULL
1.0	NULL
ml	NULL
culture	NULL
supernatant	NULL
(	NULL
100	NULL
pl	NULL
)	NULL
was	NULL
assayed	NULL
and	NULL
the	NULL
mean	NULL
of	NULL
triplicate	NULL
determinations	NULL
(	NULL
SD	NULL
<	NULL
10	NULL
%	NULL
)	NULL
is	NULL
shown	NULL
.	NULL

This	NULL
experiment	NULL
was	NULL
performed	NULL
three	NULL
times	NULL
with	NULL
similar	NULL
results	NULL
and	NULL
was	NULL
confirmed	NULL
using	NULL
a	NULL
CTLL-2	NULL
proliferation	NULL
assay	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Cells	NULL
(	NULL
1	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
activated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
1000	NULL
ng	NULL
per	NULL
well	NULL
solid	NULL
phase	NULL
)	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
(	NULL
5	NULL
ug/ml	NULL
!	NULL

fluid	NULL
phase	NULL
)	NULL
.	NULL

After	NULL
26	NULL
hr	NULL
at	NULL
37°C	NULL
,	NULL
supernatants	NULL
were	NULL
assayed	NULL
for	NULL
IL-2	NULL
.	NULL

Values	NULL
plotted	NULL
are	NULL
the	NULL
mean	NULL
of	NULL
triplicate	NULL
determinations	NULL
(	NULL
SD	NULL
<	NULL
15	NULL
%	NULL
)	NULL
.	NULL

This	NULL
experiment	NULL
was	NULL
repeated	NULL
with	NULL
similar	NULL
results	NULL
.	NULL

9550	NULL
Cell	NULL
Biology	NULL
:	NULL
Linette	NULL
et	NULL
al	NULL
.	NULL

more	NULL
BCL-2	NULL
protein	NULL
when	NULL
compared	NULL
with	NULL
parental	NULL
Jurkat	NULL
cells	NULL
as	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

When	NULL
activated	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
anti-CD3	NULL
plus	NULL
PMA	NULL
,	NULL
Jurkat/Bcl-2	NULL
cells	NULL
produce	NULL
substantially	NULL
less	NULL
IL-2	NULL
.	NULL

Production	NULL
of	NULL
IL-3	NULL
and	NULL
GM-CSF	NULL
is	NULL
also	NULL
markedly	NULL
reduced	NULL
in	NULL
Jurkat	NULL
/Be/-2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
Jurkat	NULL
T	NULL
cell	NULL
line	NULL
recapitulates	NULL
the	NULL
effects	NULL
of	NULL
BCL-2	NULL
seen	NULL
on	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
next	NULL
wished	NULL
to	NULL
assess	NULL
whether	NULL
decreased	NULL
cytokine	NULL
production	NULL
was	NULL
a	NULL
generalized	NULL
affect	NULL
that	NULL
followed	NULL
any	NULL
inhibition	NULL
of	NULL
the	NULL
apoptotic	NULL
pathway	NULL
.	NULL

The	NULL
ICE-like	NULL
cysteine	NULL
proteases	NULL
are	NULL
required	NULL
for	NULL
programmed	NULL
cell	NULL
death	NULL
,	NULL
and	NULL
small	NULL
molecules	NULL
that	NULL
inhibit	NULL
these	NULL
proteases	NULL
can	NULL
block	NULL
apoptosis	NULL
.	NULL

A	NULL
peptide-based	NULL
molecule	NULL
,	NULL
benzoxy	NULL
carbonyl-Val-Ala-Asp-fluoromethylketone	NULL
(	NULL
zZVAD-fmk	NULL
)	NULL
,	NULL
is	NULL
an	NULL
irreversible	NULL
inhibitor	NULL
particularly	NULL
potent	NULL
against	NULL
the	NULL
CPP32-like	NULL
subset	NULL
of	NULL
cysteine	NULL
proteases	NULL
.	NULL

Our	NULL
previous	NULL
studies	NULL
indicated	NULL
that	NULL
treatment	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
with	NULL
50	NULL
uM	NULL
zVAD-fmk	NULL
will	NULL
protect	NULL
them	NULL
from	NULL
anti-Fas-induced	NULL
apoptosis	NULL
and	NULL
block	NULL
the	NULL
activation	NULL
of	NULL
CPP32	NULL
(	NULL
39	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
Bci-2	NULL
,	NULL
inhibition	NULL
of	NULL
the	NULL
apoptotic	NULL
pathway	NULL
by	NULL
this	NULL
protease	NULL
inhibitor	NULL
did	NULL
not	NULL
substantially	NULL
alter	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
or	NULL
GM-CSF	NULL
production	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

BCL-2	NULL
Selectively	NULL
Impairs	NULL
NFAT	NULL
Binding	NULL
and	NULL
Nuclear	NULL
Translocation	NULL
.	NULL

NFAT	NULL
,	NULL
AP-1	NULL
,	NULL
NFxB	NULL
,	NULL
and	NULL
OCT-1	NULL
are	NULL
all	NULL
transcription	NULL
factors	NULL
required	NULL
for	NULL
optimal	NULL
IL-2	NULL
transcription	NULL
(	NULL
20	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
effect	NULL
of	NULL
BCL-2	NULL
upon	NULL
their	NULL
binding	NULL
activity	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
anti-CD3	NULL
plus	NULL
PMA	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
tested	NULL
by	NULL
electrophoretic	NULL
mobility-shift	NULL
assay	NULL
.	NULL

Interestingly	NULL
,	NULL
NFAT	NULL
binding	NULL
activity	NULL
from	NULL
activated	NULL
Jurkat/Bel-2	NULL
cells	NULL
was	NULL
substantially	NULL
diminished	NULL
when	NULL
compared	NULL
with	NULL
Jurkat/neo	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

74	NULL
)	NULL
.	NULL

Other	NULL
inducible	NULL
factors	NULL
tested	NULL
including	NULL
AP-1	NULL
and	NULL
NFKB	NULL
did	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
substantially	NULL
affected	NULL
by	NULL
BCL-2	NULL
.	NULL

Likewise	NULL
,	NULL
OCT-1	NULL
,	NULL
a	NULL
constitu-tive	NULL
octamer	NULL
binding	NULL
protein	NULL
,	NULL
remained	NULL
unaffected	NULL
by	NULL
the	NULL
expression	NULL
of	NULL
BCL-2	NULL
(	NULL
Fig	NULL
.	NULL

74	NULL
)	NULL
.	NULL

The	NULL
localization	NULL
of	NULL
NFATc3	NULL
(	NULL
NFAT	NULL
,	NULL
)	NULL
(	NULL
40	NULL
)	NULL
within	NULL
Jurkat	NULL
T	NULL
cells	NULL
was	NULL
assessed	NULL
with	NULL
a	NULL
laser-scanning	NULL
confocal	NULL
microscope	NULL
.	NULL

An	NULL
antibody	NULL
recognizing	NULL
NFATc3	NULL
revealed	NULL
it	NULL
was	NULL
predominantly	NULL
in	NULL
the	NULL
cytosol	NULL
of	NULL
either	NULL
unstimulated	NULL
Jurkat	NULL
or	NULL
unstimulated	NULL
Jurkat/Bel-2	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

Eight	NULL
hours	NULL
after	NULL
activation	NULL
,	NULL
the	NULL
NFATc3	NULL
in	NULL
Jurkat	NULL
cells	NULL
was	NULL
essentially	NULL
absent	NULL
from	NULL
the	NULL
cytosol	NULL
and	NULL
was	NULL
predominantly	NULL
present	NULL
in	NULL
clustered	NULL
aggregates	NULL
within	NULL
the	NULL
nucleus	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
NFAT	NULL
remained	NULL
prominent	NULL
in	NULL
the	NULL
cytosol	NULL
of	NULL
Jurkat	NULL
cells	NULL
and	NULL
the	NULL
NFAT	NULL
present	NULL
within	NULL
the	NULL
nucleus	NULL
displayed	NULL
a	NULL
more	NULL
finely	NULL
dispersed	NULL
pattern	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
indicated	NULL
that	NULL
the	NULL
total	NULL
level	NULL
of	NULL
NFATc3	NULL
was	NULL
comparable	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
and	NULL
Jurkat/	NULL
Bcl-2	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
Bcl-2	NULL
markedly	NULL
alters	NULL
the	NULL
activation-induced	NULL
nuclear	NULL
translocation	NULL
of	NULL
NFAT	NULL
.	NULL

BCL-2	NULL
Inhibits	NULL
NFAT-Mediated	NULL
Transactivation	NULL
.	NULL

We	NULL
next	NULL
assessed	NULL
whether	NULL
the	NULL
decreased	NULL
NFAT	NULL
translocation	NULL
and	NULL
DNA	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
binding	NULL
activity	NULL
manifested	NULL
as	NULL
impaired	NULL
NFAT-mediated	NULL
gene	NULL
transcription	NULL
.	NULL

Jurkat/neo	NULL
and	NULL
Jurkat/Bcl-2	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
either	NULL
with	NULL
the	NULL
NFAT-luciferase	NULL
construct	NULL
or	NULL
with	NULL
a	NULL
control	NULL
AP-1-luciferase	NULL
construct	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Transfected	NULL
Jurkat	NULL
cells	NULL
were	NULL
subsequently	NULL
activated	NULL
with	NULL
anti-CD3	NULL
plus	NULL
PMA	NULL
and	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
.	NULL

AP-1-mediated	NULL
transcriptional	NULL
activation	NULL
was	NULL
comparable	NULL
in	NULL
both	NULL
the	NULL
activated	NULL
Jurkat/neo	NULL
and	NULL
Jurkat/Bcl-2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
BCL-2	NULL
resulted	NULL
in	NULL
up	NULL
to	NULL
a	NULL
40-fold	NULL
suppression	NULL
of	NULL
NFAT-mediated	NULL
transactivation	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

DISCUSSION	NULL
Bci-2	NULL
genetic	NULL
models	NULL
of	NULL
altered	NULL
cell	NULL
death	NULL
provide	NULL
evidence	NULL
for	NULL
a	NULL
cell	NULL
autonomous	NULL
coordination	NULL
between	NULL
apoptosis	NULL
and	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

A	NULL
gradient	NULL
of	NULL
BCL-2	NULL
levels	NULL
revealed	NULL
a	NULL
linear	NULL
relationship	NULL
between	NULL
the	NULL
susceptibility	NULL
to	NULL
activation	NULL
and	NULL
the	NULL
vulnerability	NULL
to	NULL
death	NULL
.	NULL

The	NULL
level	NULL
of	NULL
BCL-2	NULL
dictated	NULL
the	NULL
duration	NULL
of	NULL
Go	NULL
-	NULL
>	NULL
S	NULL
phase	NULL
transition	NULL
with	NULL
a	NULL
critical	NULL
point	NULL
of	NULL
regulation	NULL
at	NULL
the	NULL
mid	NULL
G	NULL
,	NULL
phase	NULL
dependence	NULL
upon	NULL
IL-2	NULL
synthesis	NULL
and	NULL
signaling	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

Mazel	NULL
et	NULL
al	NULL
.	NULL

(	NULL
32	NULL
)	NULL
also	NULL
recently	NULL
noted	NULL
a	NULL
delay	NULL
in	NULL
the	NULL
S	NULL
phase	NULL
transition	NULL
of	NULL
Bc/-2	NULL
transgenic	NULL
cells	NULL
when	NULL
compared	NULL
with	NULL
wild	NULL
type	NULL
.	NULL

The	NULL
classical	NULL
measurements	NULL
of	NULL
mitogenesis	NULL
and	NULL
of	NULL
Gy	NULL
-	NULL
>	NULL
G	NULL
;	NULL
transition	NULL
were	NULL
not	NULL
strongly	NULL
influenced	NULL
by	NULL
BCL-2	NULL
.	NULL

Proximal	NULL
signal	NULL
transduction	NULL
events	NULL
including	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
mobilization	NULL
of	NULL
Ca**	NULL
were	NULL
quite	NULL
similar	NULL
whatever	NULL
the	NULL
BCL-2	NULL
level	NULL
.	NULL

Expression	NULL
of	NULL
immediate	NULL
early	NULL
genes	NULL
including	NULL
Myc	NULL
,	NULL
Fos	NULL
,	NULL
Jun	NULL
,	NULL
and	NULL
NGF-IB	NULL
is	NULL
a	NULL
classic	NULL
criterion	NULL
for	NULL
Go	NULL
-	NULL
>	NULL
G	NULL
,	NULL
phase	NULL
transition	NULL
,	NULL
but	NULL
was	NULL
not	NULL
altered	NULL
by	NULL
BCL-2	NULL
.	NULL

The	NULL
most	NULL
dramatic	NULL
effect	NULL
of	NULL
BCL-2	NULL
upon	NULL
T	NULL
cell	NULL
activation	NULL
was	NULL
focused	NULL
at	NULL
the	NULL
production	NULL
of	NULL
IL-2	NULL
in	NULL
mid	NULL
G	NULL
;	NULL
phase	NULL
.	NULL

The	NULL
transcription	NULL
of	NULL
IL-2	NULL
was	NULL
the	NULL
most	NULL
definable	NULL
point	NULL
of	NULL
cross	NULL
talk	NULL
between	NULL
BCL-2	NULL
and	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

Optimal	NULL
expression	NULL
of	NULL
IL-2	NULL
requires	NULL
three	NULL
inducible	NULL
transcription	NULL
factors	NULL
,	NULL
NFAT	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
NFKB	NULL
.	NULL

Any	NULL
of	NULL
these	NULL
three	NULL
might	NULL
have	NULL
been	NULL
responsible	NULL
as	NULL
prior	NULL
studies	NULL
(	NULL
these	NULL
are	NULL
provided	NULL
below	NULL
as	NULL
each	NULL
is	NULL
detailed	NULL
)	NULL
have	NULL
implicated	NULL
each	NULL
in	NULL
affecting	NULL
cell	NULL
death	NULL
.	NULL

FOS	NULL
,	NULL
which	NULL
forms	NULL
heterodimers	NULL
with	NULL
JUN	NULL
to	NULL
constitute	NULL
AP-1	NULL
,	NULL
is	NULL
expressed	NULL
after	NULL
a	NULL
variety	NULL
of	NULL
death	NULL
stimuli	NULL
(	NULL
41	NULL
)	NULL
.	NULL

NFB	NULL
appears	NULL
to	NULL
be	NULL
regulated	NULL
by	NULL
redox	NULL
and	NULL
has	NULL
also	NULL
been	NULL
implicated	NULL
in	NULL
regulating	NULL
cell	NULL
death	NULL
(	NULL
42	NULL
)	NULL
.	NULL

NFAT	NULL
is	NULL
a	NULL
transcription	NULL
factor	NULL
supracomplex	NULL
composed	NULL
of	NULL
distinct	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
subunits	NULL
that	NULL
act	NULL
in	NULL
concert	NULL
to	NULL
permit	NULL
DNA	NULL
binding	NULL
and	NULL
transcriptional	NULL
activation	NULL
(	NULL
40	NULL
,	NULL
43	NULL
,	NULL
44	NULL
)	NULL
.	NULL

NFAT-mediated	NULL
IL-2	NULL
transcription	NULL
is	NULL
complex	NULL
.	NULL

NFATp/c	NULL
rapidly	NULL
translocates	NULL
to	NULL
the	NULL
nucleus	NULL
after	NULL
Ca**	NULL
signaling	NULL
,	NULL
an	NULL
event	NULL
blocked	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
hence	NULL
requiring	NULL
the	NULL
action	NULL
of	NULL
the	NULL
phosphatase	NULL
PP2B	NULL
,	NULL
calcineurin	NULL
(	NULL
45	NULL
,	NULL
46	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
BCL-2	NULL
to	NULL
inhibit	NULL
NFAT	NULL
DNA	NULL
binding	NULL
and	NULL
impair	NULL
NFAT-mediated	NULL
gene	NULL
transcription	NULL
identifies	NULL
it	NULL
as	NULL
a	NULL
principal	NULL
site	NULL
of	NULL
BCL-2	NULL
's	NULL
influence	NULL
.	NULL

The	NULL
marked	NULL
decrease	NULL
in	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NFAT	NULL
in	NULL
6000	NULL
u	NULL
u	NULL
t	NULL
3000	NULL
T	NULL
T	NULL
400	NULL
t	NULL
t	NULL
t	NULL
-~	NULL
-	NULL
JurkaUneo	NULL
-+-	NULL
_	NULL
JurkaUnec+2VAD	NULL
-	NULL
#	NULL
-	NULL
-	NULL
Jurkat/Bci2	NULL
5000	NULL
F	NULL
i	NULL
€	NULL
300	NULL
&	NULL
4000	NULL
{	NULL
£	NULL
2000	NULL
}	NULL
1	NULL
a	NULL
&	NULL
&	NULL
a	NULL
a	NULL
a	NULL
e	NULL
e	NULL
,	NULL
3000	NULL
f	NULL
a	NULL
§	NULL
200	NULL
}	NULL
-	NULL
-	NULL
=-2000	NULL
F	NULL
7	NULL
1000	NULL
F	NULL
G	NULL
100	NULL
F	NULL
1000	NULL
F	NULL
o	NULL
hw	NULL
a*	NULL
o	NULL
l	NULL
o	NULL
e	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
10000	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
10000	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
10000	NULL
anti	NULL
CD3	NULL
(	NULL
ng/weli	NULL
)	NULL
anti	NULL
CD3	NULL
(	NULL
ng/well	NULL
)	NULL
anti	NULL
CD3	NULL
(	NULL
ng/well	NULL
)	NULL
FiG	NULL
.	NULL

6	NULL
.	NULL

-	NULL
BCL-2	NULL
but	NULL
not	NULL
zVAD-fmk	NULL
impairs	NULL
production	NULL
of	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
and	NULL
GM-CSF	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

Cells	NULL
(	NULL
1	NULL
%	NULL
10°	NULL
)	NULL
of	NULL
bulk	NULL
stably	NULL
transfected	NULL
Jurkat	NULL
T	NULL
cell	NULL
lines	NULL
were	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
1000	NULL
ng	NULL
per	NULL
well	NULL
solid	NULL
phase	NULL
)	NULL
plus	NULL
PMA	NULL
10	NULL
ng/ml	NULL
in	NULL
1	NULL
ml	NULL
complete	NULL
media	NULL
.	NULL

zVAD-fmk	NULL
was	NULL
added	NULL
to	NULL
Jurkat/neo	NULL
at	NULL
50	NULL
uM	NULL
.	NULL

After	NULL
24	NULL
hr	NULL
at	NULL
37°C	NULL
,	NULL
cell-free	NULL
supernatants	NULL
were	NULL
subjected	NULL
to	NULL
one	NULL
freeze	NULL
thaw	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
each	NULL
cytokine	NULL
using	NULL
a	NULL
capture	NULL
ELISA	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
.	NULL

Each	NULL
point	NULL
is	NULL
the	NULL
mean	NULL
of	NULL
triplicate	NULL
determinations	NULL
(	NULL
SD	NULL
<	NULL
10	NULL
%	NULL
)	NULL
for	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
or	NULL
GM-CSF	NULL
.	NULL

Cell	NULL
Biology	NULL
:	NULL
Linette	NULL
et	NULL
al	NULL
.	NULL

Jurkat/Neo	NULL
Jurkat/Bcl-2	NULL
FP	NULL
0	NULL
2	NULL
4	NULL
8	NULL
0	NULL
2	NULL
4	NULL
8	NULL
A	NULL
Jurkat/Neo	NULL
Jurkat	NULL
FP	NULL
0	NULL
2	NULL
4	NULL
8	NULL
0	NULL
2	NULL
4	NULL
8	NULL
(	NULL
hours	NULL
)	NULL
Oct-1	NULL
AP-1	NULL
NF-xB	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

-	NULL
Bcl-2	NULL
impairs	NULL
NFAT	NULL
DNA	NULL
binding	NULL
and	NULL
nuclear	NULL
translocation	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Jurkat	NULL
cells	NULL
(	NULL
~5	NULL
X	NULL
10°	NULL
per	NULL
ml	NULL
)	NULL
were	NULL
stimulated	NULL
in	NULL
T75	NULL
culture	NULL
flasks	NULL
coated	NULL
with	NULL
optimal	NULL
concentrations	NULL
of	NULL
anti-CD3	NULL
mAb	NULL
plus	NULL
PMA	NULL
for	NULL
various	NULL
times	NULL
(	NULL
0	NULL
,	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
8	NULL
hr	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
gel-shift	NULL
analysis	NULL
performed	NULL
with	NULL
2.5-5	NULL
ug	NULL
protein	NULL
extract	NULL
and	NULL
radio-labeled	NULL
DNA	NULL
probes	NULL
on	NULL
6	NULL
%	NULL
native	NULL
polyacrylamide	NULL
gels	NULL
in	NULL
0.5	NULL
%	NULL
TBE	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
9551	NULL
80	NULL
G	NULL
.J	NULL
'=	NULL
5	NULL
)	NULL
3	NULL
``	NULL
C	NULL
60	NULL
£	NULL
J	NULL
o	NULL
t	NULL
Jurkat/neo	NULL
>	NULL
40	NULL
4	NULL
's	NULL
Jurkat/Bel-2	NULL
per	NULL
[	NULL
3	NULL
<	NULL
4	NULL
&	NULL
to	NULL
20	NULL
ke	NULL
&	NULL
'	NULL
O	NULL
3	NULL
«	NULL
-d	NULL
0	NULL
t	NULL
``	NULL
I	NULL
o	NULL
.	NULL

4	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

BCL-2	NULL
impairs	NULL
NFAT-mediated	NULL
transactivation	NULL
.	NULL

Jurkat/	NULL
neo	NULL
and	NULL
Jurkat	NULL
clones	NULL
were	NULL
transiently	NULL
transfected	NULL
either	NULL
with	NULL
a	NULL
NFAT	NULL
reporter	NULL
or	NULL
with	NULL
an	NULL
AP-l-luciferase	NULL
reporter	NULL
con-struct	NULL
.	NULL

After	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
plus	NULL
PMA	NULL
,	NULL
10°	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
fold	NULL
induction	NULL
from	NULL
three	NULL
independent	NULL
assays	NULL
measuring	NULL
luciferase	NULL
activity	NULL
in	NULL
stimulated	NULL
over	NULL
unstimulated	NULL
cells	NULL
.	NULL

BCL-2-expressing	NULL
cells	NULL
suggests	NULL
this	NULL
step	NULL
as	NULL
a	NULL
major	NULL
site	NULL
of	NULL
BCL-2	NULL
regulation	NULL
.	NULL

Inhibition	NULL
of	NULL
calcineurin	NULL
by	NULL
CsA/cyclophilin	NULL
or	NULL
FK506/FKBP	NULL
indicates	NULL
that	NULL
it	NULL
is	NULL
critical	NULL
to	NULL
regulating	NULL
IL-2	NULL
and	NULL
other	NULL
cytokines	NULL
NFAT	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
TCR/CD3-mediated	NULL
cell	NULL
death	NULL
and	NULL
CsA	NULL
can	NULL
inhibit	NULL
this	NULL
apoptotic	NULL
pathway	NULL
in	NULL
T	NULL
cell	NULL
hybridomas	NULL
(	NULL
47	NULL
)	NULL
.	NULL

One	NULL
possibility	NULL
is	NULL
that	NULL
NFAT	NULL
induces	NULL
a	NULL
death	NULL
program	NULL
as	NULL
well	NULL
as	NULL
a	NULL
proliferation	NULL
program	NULL
.	NULL

While	NULL
IL-2	NULL
regulation	NULL
by	NULL
NFAT	NULL
is	NULL
a	NULL
clearly	NULL
defined	NULL
site	NULL
of	NULL
BCL-2	NULL
impact	NULL
upon	NULL
activation	NULL
,	NULL
others	NULL
could	NULL
exist	NULL
.	NULL

Other	NULL
cytokine	NULL
responses	NULL
,	NULL
IL-3	NULL
and	NULL
GM-CSF	NULL
,	NULL
were	NULL
also	NULL
abnormal	NULL
yet	NULL
also	NULL
require	NULL
NFAT	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Adding	NULL
exogenous	NULL
IL-2	NULL
to	NULL
BCL-2-expressing	NULL
T	NULL
cells	NULL
only	NULL
corrected	NULL
about	NULL
half	NULL
of	NULL
the	NULL
activation	NULL
deficit	NULL
.	NULL

This	NULL
may	NULL
reflect	NULL
the	NULL
delay	NULL
in	NULL
IL-2Ra	NULL
,	NULL
CD25	NULL
expression	NULL
also	NULL
noted	NULL
in	NULL
BCL-2	NULL
overexpressing	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Evidence	NULL
that	NULL
a	NULL
rapamycin-sensitive	NULL
intracellular	NULL
IL-2	NULL
signaling	NULL
pathway	NULL
leads	NULL
to	NULL
Bel-2	NULL
gene	NULL
induction	NULL
has	NULL
recently	NULL
been	NULL
noted	NULL
(	NULL
48	NULL
)	NULL
and	NULL
might	NULL
represent	NULL
a	NULL
feedback	NULL
control	NULL
system	NULL
.	NULL

The	NULL
level	NULL
of	NULL
BCL-2	NULL
had	NULL
a	NULL
selective	NULL
impact	NULL
upon	NULL
the	NULL
cdk	NULL
inhibitor	NULL
p27P	NULL
``	NULL
,	NULL
but	NULL
not	NULL
p21	NULL
.	NULL

Recent	NULL
evidence	NULL
indicates	NULL
that	NULL
IL-2	NULL
signaling	NULL
correlates	NULL
with	NULL
a	NULL
transition	NULL
in	NULL
cell	NULL
cycle	NULL
control	NULL
from	NULL
the	NULL
p27*	NULL
``	NULL
``	NULL
to	NULL
the	NULL
p21	NULL
cdk	NULL
inhibitor	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
.	NULL

The	NULL
cdk	NULL
inhibitors	NULL
are	NULL
felt	NULL
to	NULL
interconnect	NULL
proximal	NULL
signal	NULL
transduction	NULL
events	NULL
with	NULL
regulation	NULL
of	NULL
the	NULL
cdks	NULL
that	NULL
phosphorylate	NULL
substrates	NULL
including	NULL
retinoblastoma	NULL
and	NULL
thus	NULL
regulate	NULL
cell	NULL
cycle	NULL
(	NULL
49	NULL
,	NULL
50	NULL
)	NULL
.	NULL

Normally	NULL
,	NULL
IL-2	NULL
signaling	NULL
leads	NULL
to	NULL
the	NULL
inactivation	NULL
of	NULL
allowing	NULL
edk	NULL
activation	NULL
and	NULL
subsequent	NULL
progression	NULL
through	NULL
G	NULL
;	NULL
into	NULL
S	NULL
phase	NULL
.	NULL

The	NULL
more	NULL
rapid	NULL
loss	NULL
of	NULL
p27°P	NULL
!	NULL

in	NULL
Bel-2	NULL
If	NULL
cells	NULL
and	NULL
its	NULL
retention	NULL
in	NULL
Bcl-2	NULL
gf	NULL
cells	NULL
may	NULL
follow	NULL
from	NULL
the	NULL
altered	NULL
IL-2	NULL
production	NULL
.	NULL

Bands	NULL
were	NULL
judged	NULL
to	NULL
be	NULL
specific	NULL
(	NULL
indicated	NULL
by	NULL
arrows	NULL
)	NULL
based	NULL
on	NULL
competition	NULL
analysis	NULL
with	NULL
cold	NULL
oligonucleotides	NULL
and	NULL
supershift	NULL
with	NULL
antibodies	NULL
specific	NULL
for	NULL
each	NULL
transcription	NULL
factor	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

FP	NULL
,	NULL
free	NULL
probe	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Immucfluorescent	NULL
confocal	NULL
microscopy	NULL
of	NULL
Jurkat	NULL
cells	NULL
using	NULL
anti-NFATC3	NULL
polyclonal	NULL
antibody	NULL
.	NULL

An	NULL
unstimulated	NULL
Jurkat/	NULL
Bcl-2	NULL
clone	NULL
(	NULL
Top	NULL
)	NULL
was	NULL
indistinguishable	NULL
from	NULL
unstimulated	NULL
Jurkat/neo	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
;	NULL
Jurkat/neo	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
plus	NULL
PMA	NULL
for	NULL
8	NULL
hr	NULL
(	NULL
Middle	NULL
)	NULL
are	NULL
compared	NULL
with	NULL
stimulated	NULL
Jurkat/Bcl-2	NULL
cells	NULL
at	NULL
8	NULL
hr	NULL
(	NULL
Bottom	NULL
)	NULL
.	NULL

9552	NULL
Cell	NULL
Biology	NULL
:	NULL
Linette	NULL
et	NULL
al	NULL
.	NULL

T	NULL
Cell	NULL
Activation	NULL
pa	NULL
?	NULL

i-	NULL
p21-IL-2	NULL
Restriction	NULL
TCR/Ag	NULL
Point	NULL
Go	NULL
G1	NULL
i	NULL
S	NULL
IL-2	NULL
A4	NULL
Bcl-2	NULL
-|	NULL
NFAT	NULL
FiG	NULL
.	NULL

9	NULL
.	NULL

Schematic	NULL
representation	NULL
of	NULL
a	NULL
site	NULL
of	NULL
BCL-2	NULL
's	NULL
affect	NULL
upon	NULL
activation	NULL
.	NULL

However	NULL
,	NULL
we	NULL
can	NULL
not	NULL
formally	NULL
exclude	NULL
a	NULL
primary	NULL
effect	NULL
of	NULL
BCL-2	NULL
upon	NULL
a	NULL
cdk	NULL
inhibitor	NULL
such	NULL
as	NULL
p27P	NULL
``	NULL
.	NULL

The	NULL
influence	NULL
of	NULL
BCL-2	NULL
upon	NULL
Go	NULL
-	NULL
S	NULL
$	NULL
transition	NULL
and	NULL
upon	NULL
p27	NULL
but	NULL
not	NULL
p21	NULL
fits	NULL
well	NULL
with	NULL
the	NULL
emerging	NULL
data	NULL
that	NULL
p27	NULL
may	NULL
regulate	NULL
cdk	NULL
activity	NULL
from	NULL
quiescence	NULL
to	NULL
S	NULL
phase	NULL
,	NULL
while	NULL
p21	NULL
may	NULL
be	NULL
more	NULL
restricted	NULL
to	NULL
regulating	NULL
odk	NULL
function	NULL
in	NULL
cycling	NULL
cells	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Prior	NULL
studies	NULL
noted	NULL
little	NULL
effect	NULL
of	NULL
BCL-2	NULL
on	NULL
doubling	NULL
time	NULL
as	NULL
long	NULL
as	NULL
factor-dependent	NULL
cells	NULL
were	NULL
continuously	NULL
proliferating	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-3	NULL
.	NULL

However	NULL
,	NULL
when	NULL
cells	NULL
were	NULL
returned	NULL
to	NULL
Go	NULL
by	NULL
IL-3	NULL
deprivation	NULL
,	NULL
the	NULL
time	NULL
required	NULL
to	NULL
return	NULL
to	NULL
S	NULL
phase	NULL
following	NULL
readdition	NULL
of	NULL
IL-3	NULL
was	NULL
lengthened	NULL
by	NULL
BCL-2	NULL
(	NULL
51	NULL
,	NULL
52	NULL
)	NULL
.	NULL

The	NULL
shortened	NULL
Go	NULL
-	NULL
>	NULL
S	NULL
phase	NULL
transition	NULL
time	NULL
in	NULL
Be/-2	NULL
If	NULL
cells	NULL
described	NULL
here	NULL
argues	NULL
that	NULL
the	NULL
delays	NULL
noted	NULL
with	NULL
Be/-2	NULL
gf	NULL
are	NULL
a	NULL
primary	NULL
event	NULL
rather	NULL
than	NULL
an	NULL
artifact	NULL
of	NULL
damaged	NULL
cells	NULL
that	NULL
avoided	NULL
death	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
inability	NULL
of	NULL
a	NULL
cysteine	NULL
protease	NULL
inhibitor	NULL
to	NULL
alter	NULL
cytokine	NULL
production	NULL
also	NULL
favors	NULL
a	NULL
selective	NULL
role	NULL
for	NULL
Bc/-2	NULL
rather	NULL
than	NULL
a	NULL
secondary	NULL
effect	NULL
following	NULL
inhibition	NULL
of	NULL
apoptosis	NULL
.	NULL

What	NULL
would	NULL
be	NULL
the	NULL
teleologic	NULL
advantage	NULL
of	NULL
communication	NULL
between	NULL
cell	NULL
death	NULL
and	NULL
cell	NULL
cycle	NULL
pathways	NULL
?	NULL

Postactivation	NULL
apoptosis	NULL
accompanied	NULL
the	NULL
accelerated	NULL
cell	NULL
cycle	NULL
progression	NULL
of	NULL
Bcil-2-deficient	NULL
cells	NULL
.	NULL

This	NULL
is	NULL
reminiscent	NULL
of	NULL
the	NULL
fulminant	NULL
lym-phoid	NULL
apoptosis	NULL
noted	NULL
in	NULL
Be/-2~~	NULL
mice	NULL
(	NULL
11	NULL
)	NULL
.	NULL

However	NULL
,	NULL
even	NULL
healthy	NULL
appearing	NULL
Be/-2	NULL
knockouts	NULL
display	NULL
a	NULL
progressive	NULL
decline	NULL
in	NULL
peripheral	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
over	NULL
time	NULL
.	NULL

As	NULL
a	NULL
correlate	NULL
,	NULL
T	NULL
cell	NULL
cultures	NULL
that	NULL
are	NULL
not	NULL
stimulated	NULL
(	NULL
media	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
)	NULL
also	NULL
demonstrated	NULL
increased	NULL
death	NULL
of	NULL
Be/-2~~	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
BCL-2	NULL
loss	NULL
leads	NULL
to	NULL
immunodeficiency	NULL
both	NULL
from	NULL
an	NULL
apparently	NULL
shorter	NULL
half-life	NULL
of	NULL
resting	NULL
cells	NULL
and	NULL
from	NULL
a	NULL
susceptibility	NULL
to	NULL
postactivation-induced	NULL
death	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
excess	NULL
BCL-2	NULL
leads	NULL
to	NULL
hyperplasia	NULL
and	NULL
would	NULL
be	NULL
expected	NULL
to	NULL
save	NULL
cells	NULL
with	NULL
acquired	NULL
mutations	NULL
that	NULL
would	NULL
otherwise	NULL
be	NULL
destined	NULL
to	NULL
die	NULL
.	NULL

In	NULL
this	NULL
context	NULL
,	NULL
it	NULL
was	NULL
surprising	NULL
that	NULL
the	NULL
incidence	NULL
of	NULL
malignancies	NULL
was	NULL
relatively	NULL
low	NULL
(	NULL
12-30	NULL
%	NULL
)	NULL
and	NULL
had	NULL
a	NULL
long	NULL
latency	NULL
(	NULL
1-1.5	NULL
years	NULL
)	NULL
in	NULL
Bcl-2	NULL
transgenic	NULL
mice	NULL
(	NULL
8-10	NULL
)	NULL
.	NULL

The	NULL
growth	NULL
disadvantage	NULL
of	NULL
Bcl-2-overexpressing	NULL
cells	NULL
as	NULL
noted	NULL
here	NULL
would	NULL
help	NULL
explain	NULL
this	NULL
paradox	NULL
.	NULL

Excess	NULL
BCL-2	NULL
would	NULL
suppress	NULL
the	NULL
outgrowth	NULL
and	NULL
accumulation	NULL
of	NULL
such	NULL
death	NULL
resistant	NULL
cells	NULL
.	NULL

A	NULL
cell	NULL
autonomous	NULL
interrelationship	NULL
between	NULL
cell	NULL
death	NULL
and	NULL
cell	NULL
cycle	NULL
programs	NULL
would	NULL
provide	NULL
the	NULL
tightest	NULL
regulation	NULL
to	NULL
ensure	NULL
both	NULL
balanced	NULL
homeostasis	NULL
and	NULL
cancer	NULL
surveillance	NULL
.	NULL

G.P.L	NULL
.	NULL

and	NULL
Y.L	NULL
.	NULL

contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
Dr.	NULL
Gerald	NULL
Crabtree	NULL
for	NULL
generously	NULL
providing	NULL
luciferase	NULL
expression	NULL
constructs	NULL
,	NULL
NFATc3	NULL
Ab	NULL
,	NULL
and	NULL
helpful	NULL
discussions	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Dr.	NULL
Carl	NULL
June	NULL
in	NULL
whose	NULL
laboratory	NULL
the	NULL
[	NULL
Ca*+	NULL
]	NULL
measurements	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
assistance	NULL
of	NULL
Doug	NULL
Smoot	NULL
.	NULL

We	NULL
thank	NULL
Gary	NULL
Brown	NULL
for	NULL
animal	NULL
husbandry	NULL
and	NULL
Mary	NULL
Pichler	NULL
for	NULL
expert	NULL
preparation	NULL
of	NULL
this	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Cancer	NULL
Institute	NULL
Grant	NULL
CA	NULL
49712	NULL
.	NULL

1	NULL
.	NULL

Raff	NULL
,	NULL
M.	NULL
C.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
356	NULL
,	NULL
397-400	NULL
.	NULL

2	NULL
.	NULL

Tsujimoto	NULL
,	NULL
Y.	NULL
,	NULL
Gorham	NULL
,	NULL
J.	NULL
,	NULL
Cossman	NULL
,	NULL
J.	NULL
,	NULL
Jaffe	NULL
,	NULL
E.	NULL
&	NULL
Croce	NULL
,	NULL
C.	NULL
M.	NULL
(	NULL
1985	NULL
)	NULL
Science	NULL
229	NULL
,	NULL
1390-1393	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
Bakhshi	NULL
,	NULL
A.	NULL
,	NULL
Jensen	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Goldman	NULL
,	NULL
P.	NULL
,	NULL
Wright	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
McBride	NULL
,	NULL
O.	NULL
W.	NULL
,	NULL
Epstein	NULL
,	NULL
A.	NULL
L.	NULL
&	NULL
Korsmeyer	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Cell	NULL
41	NULL
,	NULL
899-906	NULL
.	NULL

Cleary	NULL
,	NULL
M.	NULL
L.	NULL
&	NULL
Sklar	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82	NULL
,	NULL
7439-7443	NULL
.	NULL

Vaux	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Cory	NULL
,	NULL
S.	NULL
&	NULL
Adams	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
335	NULL
,	NULL
440-442	NULL
.	NULL

McDonnell	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Deane	NULL
,	NULL
N.	NULL
,	NULL
Platt	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
Nunez	NULL
,	NULL
G.	NULL
,	NULL
Jaeger	NULL
,	NULL
U.	NULL
,	NULL
McKearn	NULL
,	NULL
J.	NULL
P.	NULL
&	NULL
Korsmeyer	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Cell	NULL
57	NULL
,	NULL
79-88	NULL
.	NULL

Hockenbery	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Nufiez	NULL
,	NULL
G.	NULL
,	NULL
Milliman	NULL
,	NULL
C.	NULL
,	NULL
Schreiber	NULL
,	NULL
R.	NULL
D.	NULL
&	NULL
Korsmeyer	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
348	NULL
,	NULL
334-336	NULL
.	NULL

McDonnell	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

&	NULL
Korsmeyer	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
349	NULL
,	NULL
254-256	NULL
.	NULL

Strasser	NULL
,	NULL
A.	NULL
,	NULL
Harris	NULL
,	NULL
A.	NULL
W.	NULL
&	NULL
Cory	NULL
,	NULL
S.	NULL
(	NULL
1993	NULL
)	NULL
Oncogene	NULL
8	NULL
,	NULL
1-9	NULL
.	NULL

Linette	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Hess	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Sentman	NULL
,	NULL
C.	NULL
L.	NULL
&	NULL
Korsmeyer	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Blood	NULL
86	NULL
,	NULL
1255-1260	NULL
.	NULL

Veis	NULL
,	NULL
D.	NULL
,	NULL
Sorenson	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Shutter	NULL
,	NULL
J.	NULL
R.	NULL
&	NULL
Korsmeyer	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Cell	NULL
75	NULL
,	NULL
229-240	NULL
.	NULL

Ma	NULL
,	NULL
A.	NULL
,	NULL
Pena	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Chang	NULL
,	NULL
B.	NULL
,	NULL
Margosian	NULL
,	NULL
E.	NULL
,	NULL
Davidson	NULL
,	NULL
L.	NULL
,	NULL
Alt	NULL
,	NULL
F.	NULL
W.	NULL
&	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
,	NULL
4763-4767	NULL
.	NULL

Motoyama	NULL
,	NULL
N.	NULL
,	NULL
Wang	NULL
,	NULL
F.	NULL
,	NULL
Roth	NULL
,	NULL
K.	NULL
,	NULL
Sawa	NULL
,	NULL
H.	NULL
,	NULL
Nakayama	NULL
,	NULL
K.	NULL
,	NULL
Nakayama	NULL
,	NULL
K.	NULL
,	NULL
Negishi	NULL
,	NULL
I.	NULL
,	NULL
Senju	NULL
,	NULL
S.	NULL
&	NULL
Loh	NULL
,	NULL
D.	NULL
Y	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Science	NULL
267	NULL
,	NULL
1506-1510	NULL
.	NULL

Evan	NULL
,	NULL
G.	NULL
I.	NULL
,	NULL
Wyllie	NULL
,	NULL
A.	NULL
H.	NULL
,	NULL
Gilbert	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
Littlewood	NULL
,	NULL
T.	NULL
D.	NULL
,	NULL
Land	NULL
,	NULL
H.	NULL
,	NULL
Brooks	NULL
,	NULL
M.	NULL
,	NULL
Waters	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Penn	NULL
,	NULL
L.	NULL
Z	NULL
.	NULL

&	NULL
Hancock	NULL
,	NULL
D.	NULL
C.	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
69	NULL
,	NULL
119-128	NULL
.	NULL

Harrington	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Bennett	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Fanidi	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Evan	NULL
,	NULL
G.	NULL
I	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
EMBO	NULL
J	NULL
994	NULL
,	NULL
3286-3295	NULL
.	NULL

Lee	NULL
,	NULL
E.	NULL
Y.	NULL
,	NULL
-H.	NULL
P.	NULL
,	NULL
Chang	NULL
,	NULL
C.	NULL
Y.	NULL
,	NULL
Hu	NULL
,	NULL
N.	NULL
,	NULL
Wange	NULL
,	NULL
Y.-C.	NULL
J.	NULL
,	NULL
Lai	NULL
,	NULL
C.-C.	NULL
,	NULL
Herrup	NULL
,	NULL
K.	NULL
,	NULL
Lee	NULL
,	NULL
W.-H.	NULL
&	NULL
Bradley	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
359	NULL
,	NULL
288-294	NULL
.	NULL

Jacks	NULL
,	NULL
T.	NULL
,	NULL
Fazeli	NULL
,	NULL
A.	NULL
,	NULL
Schmitt	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
Bronson	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
Goodell	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

&	NULL
Weinberg	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
359	NULL
,	NULL
295-300	NULL
.	NULL

Shan	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Lee	NULL
,	NULL
B.-H.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
8166-8173	NULL
.	NULL

Qin	NULL
,	NULL
X.-Q	NULL
.	NULL

,	NULL
Livingston	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Kaelin	NULL
,	NULL
W.	NULL
G.	NULL
&	NULL
Adams	NULL
,	NULL
P.	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91	NULL
,	NULL
10918-10922	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Strauss	NULL
,	NULL
D.	NULL
&	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
14	NULL
,	NULL
357-362	NULL
.	NULL

Pardee	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
603-608	NULL
.	NULL

Linette	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Grusby	NULL
,	NULL
M.J.	NULL
,	NULL
Hedrick	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Hansen	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
Glimcher	NULL
,	NULL
L.	NULL
H.	NULL
&	NULL
Korsmeyer	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Immunity	NULL
1	NULL
,	NULL
197-205	NULL
.	NULL

Abe	NULL
,	NULL
R.	NULL
,	NULL
Vandenberghe	NULL
,	NULL
P.	NULL
,	NULL
Craighead	NULL
,	NULL
N.	NULL
,	NULL
Smoot	NULL
,	NULL
D.	NULL
S.	NULL
,	NULL
Lee	NULL
,	NULL
K.	NULL
P.	NULL
&	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

154	NULL
,	NULL
985-997	NULL
.	NULL

June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Fletcher	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

&	NULL
Samelson	NULL
,	NULL
L.	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

144	NULL
,	NULL
1591-1599	NULL
.	NULL

Weiss	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Stobo	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
J	NULL
;	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

160	NULL
,	NULL
1284-1299	NULL
.	NULL

Carayon	NULL
,	NULL
P.	NULL
&	NULL
Bord	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
147	NULL
,	NULL
225-230	NULL
.	NULL

Montgomery	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

&	NULL
Dallman	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

147	NULL
,	NULL
554-560	NULL
.	NULL

Fiering	NULL
,	NULL
S.	NULL
,	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Mattila	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
&	NULL
Herzenberg	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

4	NULL
,	NULL
1823-1834	NULL
.	NULL

Mattila	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Fiering	NULL
,	NULL
S.	NULL
,	NULL
Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
McCutcheon	NULL
,	NULL
M.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
&	NULL
Herzenberg	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

9	NULL
,	NULL
4425-4433	NULL
.	NULL

Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Kunkel	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
Emerson	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
Leiden	NULL
,	NULL
J.	NULL
M.	NULL
&	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
1333-1337.	NULL
.	NULL

Gavrieli	NULL
,	NULL
Y.	NULL
,	NULL
Sherman	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Ben-Sasson	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

119	NULL
,	NULL
493-501	NULL
.	NULL

Mazel	NULL
,	NULL
S.	NULL
,	NULL
Burtrum	NULL
,	NULL
D.	NULL
&	NULL
Petrie	NULL
,	NULL
H.	NULL
T.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183	NULL
,	NULL
2219-2226	NULL
.	NULL

Polyak	NULL
,	NULL
K.	NULL
,	NULL
Lee	NULL
,	NULL
M.-H.	NULL
,	NULL
Erdjument-Bromage	NULL
,	NULL
H.	NULL
,	NULL
Koff	NULL
,	NULL
A.	NULL
,	NULL
Roberts	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
&	NULL
Massagué	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cell	NULL
78	NULL
,	NULL
59-66	NULL
.	NULL

Toyoshima	NULL
,	NULL
H.	NULL
&	NULL
Hunter	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
78	NULL
,	NULL
67-74	NULL
.	NULL

Harper	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Adami	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Wei	NULL
,	NULL
N.	NULL
,	NULL
Keyomarsi	NULL
,	NULL
K.	NULL
&	NULL
Elledge	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Cell	NULL
75	NULL
,	NULL
805-816	NULL
.	NULL

El-Deiry	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
Tokino	NULL
,	NULL
T.	NULL
,	NULL
Velculescu	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
Levy	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Parsons	NULL
,	NULL
R.	NULL
,	NULL
Trent	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Lin	NULL
,	NULL
D.	NULL
,	NULL
Mercer	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
Kinzler	NULL
,	NULL
K.	NULL
W.	NULL
&	NULL
Vogelstein	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Cell	NULL
75	NULL
,	NULL
817-825	NULL
.	NULL

Firpo	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
Koff	NULL
,	NULL
A.	NULL
,	NULL
Solomon	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

&	NULL
Roberts	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
4889-4901	NULL
.	NULL

Nourse	NULL
,	NULL
J.	NULL
,	NULL
Firpo	NULL
,	NULL
E.	NULL
,	NULL
Flanagan	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Coats	NULL
,	NULL
S.	NULL
,	NULL
Polyak	NULL
,	NULL
K.	NULL
,	NULL
Lee	NULL
,	NULL
M.-H.	NULL
,	NULL
Massague	NULL
,	NULL
J.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
&	NULL
Roberts	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
372	NULL
,	NULL
570-573	NULL
.	NULL

Armstrong	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Aja	NULL
,	NULL
T.	NULL
,	NULL
Xiang	NULL
,	NULL
J.	NULL
,	NULL
Gaur	NULL
,	NULL
S.	NULL
,	NULL
Krebs	NULL
,	NULL
J.	NULL
,	NULL
Hoang	NULL
,	NULL
K.	NULL
,	NULL
Bai	NULL
,	NULL
X	NULL
,	NULL
Korsmeyer	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Karanewsky	NULL
,	NULL
D.	NULL
S.	NULL
,	NULL
Fritz	NULL
,	NULL
L.	NULL
C.	NULL
&	NULL
Tomaselli	NULL
,	NULL
K.	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
16850-16855	NULL
.	NULL

Ho	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
Thomas	NULL
,	NULL
D.J	NULL
.	NULL

,	NULL
Timmerman	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Li	NULL
,	NULL
X.	NULL
,	NULL
Francke	NULL
,	NULL
V.	NULL
&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
19898-19907	NULL
.	NULL

Smeyne	NULL
,	NULL
R.J.	NULL
,	NULL
Vendrell	NULL
,	NULL
M.	NULL
,	NULL
Hayward	NULL
,	NULL
M.	NULL
,	NULL
Baker	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
Miao	NULL
,	NULL
G.	NULL
G.	NULL
,	NULL
Schilling	NULL
,	NULL
K.	NULL
,	NULL
Robertson	NULL
,	NULL
L.	NULL
,	NULL
Curran	NULL
,	NULL
T.	NULL
&	NULL
Morgan	NULL
,	NULL
J.	NULL
I	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
363	NULL
,	NULL
166-169	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
Henkel	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12	NULL
,	NULL
141-179	NULL
.	NULL

Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
15	NULL
,	NULL
274-281	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
&	NULL
Clipstone	NULL
,	NULL
N.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

63	NULL
,	NULL
1045-1083	NULL
.	NULL

O'Keefe	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Tamura	NULL
,	NULL
J.	NULL
,	NULL
Kincaid	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Tocci	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

&	NULL
O'Neill	NULL
,	NULL
E.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
357	NULL
,	NULL
692-694	NULL
.	NULL

Clipstone	NULL
,	NULL
N.	NULL
A	NULL
.	NULL

&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
357	NULL
,	NULL
695-697	NULL
.	NULL

Fruman	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

&	NULL
Bicrer	NULL
,	NULL
B.	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
FASEB	NULL
J	NULL
.	NULL

8	NULL
,	NULL
391-400	NULL
.	NULL

Miyazaki	NULL
,	NULL
T.	NULL
,	NULL
Liu	NULL
,	NULL
Z.-J	NULL
.	NULL

,	NULL
Kawahara	NULL
,	NULL
A.	NULL
,	NULL
Minami	NULL
,	NULL
Y.	NULL
,	NULL
Yamada	NULL
,	NULL
K.	NULL
,	NULL
Tsujimoto	NULL
,	NULL
Y.	NULL
,	NULL
Barsoumian	NULL
,	NULL
E.	NULL
L.	NULL
,	NULL
Perlmutter	NULL
,	NULL
R.	NULL
M.	NULL
&	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
81	NULL
,	NULL
223-231	NULL
.	NULL

Weinberg	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Cell	NULL
81	NULL
,	NULL
323-330	NULL
.	NULL

Sherr	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

&	NULL
Roberts	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

9	NULL
,	NULL
1149-1163	NULL
.	NULL

Nunez	NULL
,	NULL
G.	NULL
,	NULL
London	NULL
,	NULL
L.	NULL
,	NULL
Hockenbery	NULL
,	NULL
D.	NULL
,	NULL
Alexander	NULL
,	NULL
M.	NULL
,	NULL
McKearn	NULL
,	NULL
J.	NULL
P.	NULL
&	NULL
Korsmeyer	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

144	NULL
,	NULL
3602-3610	NULL
.	NULL

Marvel	NULL
,	NULL
J.	NULL
,	NULL
Perkins	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Rivas	NULL
,	NULL
A.	NULL
L.	NULL
&	NULL
Collins	NULL
,	NULL
M.	NULL
K.	NULL
L.	NULL
(	NULL
1994	NULL
)	NULL
Oncogene	NULL
9	NULL
,	NULL
1117-1122	NULL
.	NULL

